<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03085758</url>
  </required_header>
  <id_info>
    <org_study_id>ADR-02</org_study_id>
    <nct_id>NCT03085758</nct_id>
  </id_info>
  <brief_title>Treatment of Patients With Early Septic Shock and Bio-Adrenomedullin(ADM) Concentration &gt; 70 pg/ml With ADRECIZUMAB</brief_title>
  <acronym>AdrenOSS-2</acronym>
  <official_title>A Double-Blind, Placebo-Controlled, Randomized, Multicenter, Proof of Concept and Dose-Finding Phase II Clinical Trial to Investigate the Safety, Tolerability and Efficacy of ADRECIZUMAB in Patients With Septic Shock and Elevated Adrenomedullin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adrenomed AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Adrenomed AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blind, placebo-controlled, randomized, multicenter proof of concept and&#xD;
      dose-finding phase II study using two doses of ADRECIZUMAB in patients with early septic&#xD;
      shock and a bio-ADM plasma concentration at admission of &gt; 70 pg/ml.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind, placebo-controlled, randomized, multicenter proof of concept and&#xD;
      dose-finding phase II study using two doses of ADRECIZUMAB in patients with early septic&#xD;
      shock and a bio-ADM plasma concentration at admission of &gt; 70 pg/ml.&#xD;
&#xD;
      &quot;Early&quot; septic shock is defined as a life-threatening organ dysfunction due to dysregulated&#xD;
      host response to a proven or suspected infection which leads to a decline of Mean Arterial&#xD;
      Pressure (MAP) &lt; 65 mmHg, which is refractory to fluid resuscitation and requires&#xD;
      vasopressors. Early is defined as a maximum of less than 12 hours between onset of the&#xD;
      cardiovascular organ-dysfunction and administration of ADRECIZUMAB. Refractoriness to fluid&#xD;
      resuscitation is defined as a lack of response to the administration of 30 mL of fluid per&#xD;
      kilogram of body weight or is determined according to a clinician's assessment of inadequate&#xD;
      hemodynamic results.&#xD;
&#xD;
      It is intended to enroll 300 patients from surgical, medical and mixed ICU at multiple&#xD;
      centers in Europe.&#xD;
&#xD;
      All patients will be treated according to &quot;International Guidelines for Management of Severe&#xD;
      Sepsis and Septic Shock&quot;.&#xD;
&#xD;
      Eligible patients (confirmed by central verification) will be randomized (1:1:2) to&#xD;
      ADRECIZUMAB treatment arm A (2 mg/kg) or to ADRECIZUMAB treatment arm B (4 mg/kg) or to&#xD;
      placebo as control group. Patients assigned to the treatment arm A or B will be administered&#xD;
      a single dose of ADRECIZUMAB as intravenous infusion over approximately 1 hour; patients&#xD;
      assigned to the control group will be administered placebo as intravenous infusion over&#xD;
      approximately 1 hour.&#xD;
&#xD;
      As long as the patients are on the ICU, daily measurements of clinical signs and laboratory&#xD;
      data will be collected for safety reasons and for determination of Sequential Organ Failure&#xD;
      Assessment Score (SOFA score). Additional blood samples for central laboratory analyses will&#xD;
      be taken at inclusion on day 1, day 3, day 5, day 7 or day of discharge (whatever comes&#xD;
      first) for measurement of biomarkers.&#xD;
&#xD;
      The SOFA score and its components will be determined daily for all patients over the entire&#xD;
      stay on the ICU (28 days or until discharge whatever comes first). Safety monitoring for each&#xD;
      patient will begin at the time of signing the Informed Consent Form and continue for 90 days&#xD;
      after end of short-term infusion of study medication.&#xD;
&#xD;
      At selected study centers a pharmacokinetic (PK) substudy will be performed to determine the&#xD;
      profile of ADRECIZUMAB in 80 randomized patients.&#xD;
&#xD;
      An interim analysis for efficacy is planned after 50% of patients have completed the study&#xD;
      (n=150).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 12, 2017</start_date>
  <completion_date type="Actual">December 20, 2019</completion_date>
  <primary_completion_date type="Actual">December 20, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double Blind, Placebo-Controlled, Randomized, Multicenter Proof of Concept and Dose-Finding Phase II Clinical Trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endpoints for Primary Objective (Safety and Tolerability of Adrecizumab: Mortality)</measure>
    <time_frame>90 days</time_frame>
    <description>The endpoints for the primary objective is mortality evaluated over the 90 days study period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Endpoints for Primary Objective (Safety and Tolerability of Adrecizumab: Interruption of Infusion)</measure>
    <time_frame>90 days</time_frame>
    <description>The endpoints for the primary objective are to determine over the 90 days study period: Interruption of infusion due to intolerability of ADRECIZUMAB</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Endpoints for Primary Objective (Safety and Tolerability of Adrecizumab: Frequency of TEAEs)</measure>
    <time_frame>90 days</time_frame>
    <description>The endpoints for the primary objective are to determine over the 90 days study period. Number of participants with treatment-emergent adverse events per treatment group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Endpoints for Primary Objective (Safety and Tolerability of Adrecizumab: Severity and Frequency of TEAEs) - Mild Severity</measure>
    <time_frame>90 days</time_frame>
    <description>The endpoints for the primary objective are to determine over the 90 days study period. Number of participants with treatment-emergent adverse events per treatment group with mild severity treatment emergent events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Endpoints for Primary Objective (Safety and Tolerability of Adrecizumab: Severity and Frequency of TEAEs) - Moderate Severity</measure>
    <time_frame>90 days</time_frame>
    <description>The endpoints for the primary objective are to determine over the 90 days study period. Number of participants with treatment-emergent adverse events per treatment group with moderate severity treatment emergent events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Endpoints for Primary Objective (Safety and Tolerability of Adrecizumab: Severity and Frequency of TEAEs) - Severe Severity</measure>
    <time_frame>90 days</time_frame>
    <description>The endpoints for the primary objective are to determine over the 90 days study period. Number of participants with treatment-emergent adverse events per treatment group with severe severity treatment emergent events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy to be Determined by Sepsis Support Index (SSI)</measure>
    <time_frame>14 days</time_frame>
    <description>The primary efficacy endpoint of this study is the Sepsis Support Index (SSI) defined as: days with organ support or dead within 14 day follow up More precisely: In the time frame of 14 day follow-up, each day on support with vasopressor, and/or mechanical ventilation, and/or renal dysfunction (defined as renal SOFA = 4), or not alive, is counted as 1. The sum over the follow up period is defined as SSI.&#xD;
Minimum value possible is 0, maximum value is 14. A higher score means a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sepsis Support Index (SSI)</measure>
    <time_frame>28 days</time_frame>
    <description>Sepsis Support Index (SSI) at 28 day follow-up Minimum value possible is 0, maximum value is 14. A higher score means a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Penalized Sepsis Support Index (pSSI) at 14 Day Follow-up</measure>
    <time_frame>day 14</time_frame>
    <description>Penalized Sepsis Support Index (pSSI) at day 14, defined similar to the SSI with the exception that patients that die get penalized by assigning the maximum value, i.e. the pSSI is set to 14 or 28, respectively.&#xD;
Minimum value possible is 0, maximum value is 14. A higher score means a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistent Organ Dysfunction or Death at 14 and 28 Day Follow-up</measure>
    <time_frame>day 14 and day 28</time_frame>
    <description>Persistent organ dysfunction or death at 14 and 28 day follow-up. Count of participants with either persistent organ dysfunction or death at Day 14 and Day 28. Persistent Organ Dysfunction is defined as the persistence of organ dysfunction requiring supportive technologies during the convalescent phase of critical illness and it is present when a patient has an ongoing requirement for vasopressors, dialysis, or mechanical ventilation at the outcome assessments time points, as defined by Heyland et al.; Persistent organ dysfunction plus death: a novel,composite outcome measure for critical care trials. Critical Care 2011, 15.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality Rate</measure>
    <time_frame>day 28</time_frame>
    <description>Day 28 mortality rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SSI and pSSI Excluding the Renal Component</measure>
    <time_frame>day 14 and day 28</time_frame>
    <description>Sepsis Support Index (SSI) and penalized Sepsis Support Index (pSSI) excluding the renal component. pSSI is a version of the SSI where mortality is given extra weight: Patients being alive during the 14 days' follow up will have an SSI ranging up to 14, while patients who died within that period will be assigned a score of &quot;14 plus the number of days not being alive&quot;. Thus the SSI and pSSI score may range between zero and 28. A higher score means a worse outcome. The number of participants analyzed differs per row due to missing data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SSI Weighted for Mortality</measure>
    <time_frame>day 14</time_frame>
    <description>Sepsis Support Index (SSI) Weighted for Mortality. Minimum value possible is 0, maximum value is 14. A higher score means a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual Sepsis Support Index Components</measure>
    <time_frame>day 14 and day 28</time_frame>
    <description>Individual Sepsis Support Index (SSI) components (hemodynamic, respiratory and renal failure) with and without mortality.&#xD;
Minimum value possible is 0, maximum value is 14. A higher score means a worse outcome. The number of participants analyzed differs per row due to missing data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sequential Organ Failure Assessment (SOFA) Score : Composite Measure: SOFA Score and Its Changes Over Time</measure>
    <time_frame>28 days</time_frame>
    <description>Sequential Organ Failure Assessment (SOFA) Score:&#xD;
SOFA score change at Day 3 - baseline, delta = difference between maximum and minimum score during ICU stay, mean/maximum/total daily score during ICU stay, SOFA-3 (score limited to cardiovascular, respiratory and renal function). Measured at baseline and Day 3.&#xD;
SOFA score: Minimum possible score is 0, maximum is 24. A higher score meas a worse outcome. Measured at baseline, Day 2 to Day 28.&#xD;
SOFA-3 score: Minimum possible score is 0, maximum is 12. A higher score meas a worse outcome. Measured at baseline, Day 2 to Day 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Renal Function (Creatinine)</measure>
    <time_frame>day 1, day 3 and day 7</time_frame>
    <description>Change in renal function as change in creatinine (day 3 - day 1, day 7 - day 1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Stay at ICU/ Hospital</measure>
    <time_frame>90 days</time_frame>
    <description>Duration of stay at ICU / hospital. The number of participants analyzed differs per row due to missing data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Functional Parameter Mean Arterial Pressure During Stay at ICU</measure>
    <time_frame>28 days</time_frame>
    <description>Changes of Mean Arterial Pressure (MAP). Change from baseline to day 28/last day in ICU was calculated (value at day 28 or last collected value minus value at baseline). MAP was collected at screening and daily from day 1 to day 28 or discharge as well as on the follow-up visit day 28. Vital signs were assessed as min/max values within 24 hours except at screening and on the follow-up visit day 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Functional Parameter Creatinine During Stay at ICU</measure>
    <time_frame>28 days</time_frame>
    <description>Changes of creatinine. Measurement for baseline and Day 28 given. Creatinine was measured in the daily blood sample during ICU stay until discharge or Day 28 in a local laboratory assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Functional Parameter Partial Pressure of Oxygen in Arterial Blood(PaO2) / Fraction of Inspired Oxygen (FiO2) During Stay at ICU</measure>
    <time_frame>28 days</time_frame>
    <description>Changes of Partial Pressure of Oxygen in Arterial Blood (PaO2) / Fraction of inspired oxygen (FiO2) from baseline to the last observed value are measured. PaO2 and FiO2 was collected if an arterial line was in place. The arterial blood was assessed for PaO2 and FiO2. Both were measured in mmHg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Functional Parameter Blood Lactate During Stay at ICU</measure>
    <time_frame>28 days</time_frame>
    <description>Changes of blood lactate from baseline to Day 28 or discharge. Blood lactate was measured in the daily blood sample from baseline to ICU discharge or until Day 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Functional Parameter Fluid Balance During Stay at ICU</measure>
    <time_frame>28 days</time_frame>
    <description>Changes of fluid balance - Last Observed Value. Percentage of Participants with low (&lt;/=1000 mL) and high (&gt;1000 mL) Fluid balance at the last observed value.&#xD;
Daily fluid intake will be calculated as the sum of all intravenous and oral fluids. The daily fluid output will be calculated as the sum of the volume of urine output, ultrafiltration fluid, drain fluid, and estimated gastrointestinal losses (including stools only in the presence of profound diarrhea). Insensitive losses will not be taken into account because they are difficult to assess reliably. Daily fluid balance (according to baseline patient weight) will be calculated by subtracting the total fluid output from the total intake.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Functional Parameter Mid-Regional Pro-Adrenomedullin (MR-proADM) During Stay at ICU</measure>
    <time_frame>28 days</time_frame>
    <description>Changes of Mid-Regional pro-Adrenomedullin (MR-proADM) between baseline and last observed value. MR-proADM was measured in the blood samples taken during the ICU stay prior to start of IMP infusion (day 1) and within the time frame of 24 hours (+/- 10 hours) after end of IMP infusion (day 2), at 48 hours, 96 hours and 144 hours after end of infusion (+/- 10 hours) or between scheduled assessments, if discharged earlier from ICU (whatever comes first).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Functional Parameter Inflammatory Marker Procalcitonine (PCT) During Stay at ICU</measure>
    <time_frame>28 days</time_frame>
    <description>Changes of inflammatory marker Procalcitonine (PCT) between baseline and last observed value. PCT was measured in the blood samples taken during the ICU stay prior to start of IMP infusion (day 1) and within the time frame of 24 hours (+/- 10 hours) after end of IMP infusion (day 2), at 48 hours, 96 hours and 144 hours after end of infusion (+/- 10 hours) or between scheduled assessments, if discharged earlier from ICU (whatever comes first).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Functional Parameter Inflammatory Marker Interleukin-6 (IL-6) During Stay at ICU</measure>
    <time_frame>28 days</time_frame>
    <description>Changes of inflammatory marker Interleukin-6 (IL-6) between baseline and last observed value. IL-6 was measured in the blood samples taken during the ICU stay prior to start of IMP infusion (day 1) and within the time frame of 24 hours (+/- 10 hours) after end of IMP infusion (day 2), at 48 hours, 96 hours and 144 hours after end of infusion (+/- 10 hours) or between scheduled assessments, if discharged earlier from ICU (whatever comes first).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Functional Parameter Dipeptidyl Peptidase 3 (DPP3) During Stay at ICU</measure>
    <time_frame>28 days</time_frame>
    <description>Changes of dipeptidyl peptidase 3 (DPP3) between baseline and last observed value. DPP3 was measured in the blood samples taken during the ICU stay prior to start of IMP infusion (day 1) and within the time frame of 24 hours (+/- 10 hours) after end of IMP infusion (day 2), at 48 hours, 96 hours and 144 hours after end of infusion (+/- 10 hours) or between scheduled assessments, if discharged earlier from ICU (whatever comes first).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vasopressor Use (Drug, Highest Dose)</measure>
    <time_frame>28 days</time_frame>
    <description>Vasopressor use (drug, highest dose). Vasopressor use was recorded from admission to ICU at time point of diagnosis of septic shock and daily thereafter from day 1 through day 28 or discharge from ICU (whatever comes first).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcomes : Quality of Life by Euro-QoL-5</measure>
    <time_frame>day 28 and day 90</time_frame>
    <description>Patient reported outcomes: Quality of Life Form by EuroQoL Group, version &quot;Euro-QoL-5&quot; (day 28 and day 90). Change 1 = Visual analog scale (VAS) at discharge - VAS at day 90. Change 2 = VAS at day 28 - VAS at day 90. Minimum value on the scale is 0, maximum value on the scale is 100. A lower score indicates a worse outcome. As the change between two scores is calculated, a negative number indicates a worsening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs</measure>
    <time_frame>7 days</time_frame>
    <description>Vital signs: heart rate (beat per minute) Change from baseline to Day 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Penalized Sepsis Support Index (pSSI) at 28 Day Follow-up</measure>
    <time_frame>day 28</time_frame>
    <description>Penalized Sepsis Support Index (pSSI) at 28 day follow-up, is a version of the SSI where mortality is given extra weight: Patients being alive duringthe 14 days' follow up will have an SSI ranging up to 14 (as defined above), while patients who died within that period will be assigned a score of &quot;14 plus the number of days not being alive&quot;. Thus the weighted SSI score may range between zero and 28. A higher score means a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vasopressor Use (Drug, Lowest Dose)</measure>
    <time_frame>28 days</time_frame>
    <description>Vasopressor use (drug, lowest dose). Vasopressor use was recorded from admission to ICU at time point of diagnosis of septic shock and daily thereafter from day 1 through day 28 or discharge from ICU (whatever comes first).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vasopressor Use (Drug, Duration)</measure>
    <time_frame>28 days</time_frame>
    <description>Vasopressor use (drug, duration). Vasopressor use was recorded from admission to ICU at time point of diagnosis of septic shock and daily thereafter from day 1 through day 28 or discharge from ICU (whatever comes first).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Renal Function (penKid)</measure>
    <time_frame>day 1, day 3 and day 7</time_frame>
    <description>Change in renal function as change in penKid (day 3 - day 1, day 7 - day 1). penKid was measured in the blood samples taken during the ICU stay prior to start of IMP infusion (day 1) and within the time frame of 24 hours (+/- 10 hours) after end of IMP infusion (day 2), at 48 hours, 96 hours and 144 hours after end of infusion (+/- 10 hours) or between scheduled assessments, if discharged earlier from ICU (whatever comes first).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs - Blood Pressure</measure>
    <time_frame>7 days</time_frame>
    <description>Vital signs: blood pressure - mean arterial pressure (MAP) mmHg Change from baseline to Day 7.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>In Sub-study Key Pharmacokinetic Parameters Peak Plasma Concentrations (Cmax) Are to be Determined in 80 Patients</measure>
    <time_frame>28 days</time_frame>
    <description>peak plasma concentrations (Cmax). Time points at which blood samples were taken prior IMP administration, at 30 min, 24 hrs, 48 hrs , 96 hrs, 144 hrs, 648 hrs after IMP administration.</description>
  </other_outcome>
  <other_outcome>
    <measure>In Sub-study Key Pharmacokinetic Parameters Time to Cmax (Tmax) Are to be Determined in 80 Patients</measure>
    <time_frame>28 days</time_frame>
    <description>Time to Cmax (tmax) in hours (h)</description>
  </other_outcome>
  <other_outcome>
    <measure>In Sub-study Key Pharmacokinetic Parameter AUC is to be Determined in 80 Patients</measure>
    <time_frame>28 days</time_frame>
    <description>systemic exposure : Area under the plasma concentration versus time curve (AUC). Time points at which blood samples were taken prior IMP administration, at 30 min, 24 hrs, 48 hrs , 96 hrs, 144 hrs, 648 hrs after IMP administration.</description>
  </other_outcome>
  <other_outcome>
    <measure>In Sub-study Key Pharmacokinetic Parameter Volume of Distribution is to be Determined in 80 Patients</measure>
    <time_frame>28 days</time_frame>
    <description>volume of distribution (V). Time points at which blood samples were taken prior IMP administration, at 30 min, 24 hrs, 48 hrs , 96 hrs, 144 hrs, 648 hrs after IMP administration.</description>
  </other_outcome>
  <other_outcome>
    <measure>In Sub-study Key Pharmacokinetic Parameter Systemic Clearance is to be Determined in 80 Patients</measure>
    <time_frame>28 days</time_frame>
    <description>systemic clearance (CL). Time points at which blood samples were taken prior IMP administration, at 30 min, 24 hrs, 48 hrs , 96 hrs, 144 hrs, 648 hrs after IMP administration.</description>
  </other_outcome>
  <other_outcome>
    <measure>In Sub-study Key Pharmacokinetic Parameter Elimination Half-life is to be Determined in 80 Patients</measure>
    <time_frame>28 days</time_frame>
    <description>elimination half-life (t½). Time points at which blood samples were taken prior IMP administration, at 30 min, 24 hrs, 48 hrs , 96 hrs, 144 hrs, 648 hrs after IMP administration.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">301</enrollment>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>Treatment Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 2 mg/kg Adrecizumab (treatment arm A)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 4 mg/kg Adrecizumab (treatment arm B)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intravenous infusion over approximately 1 hour of single i.v. dose of Placebo of Adrecizumab (control group)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adrecizumab</intervention_name>
    <description>Single i.v. dose of 2 mg/kg (treatment arm A) or 4 mg/kg (treatment arm B)</description>
    <arm_group_label>Treatment Arm A</arm_group_label>
    <arm_group_label>Treatment Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single i.v. dose of placebo (control group)</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent by patient or legal representative (according to country -&#xD;
             specific regulations)&#xD;
&#xD;
          2. Male and female patient, age ≥ 18 years&#xD;
&#xD;
          3. Body weight 50 kg - 120 kg&#xD;
&#xD;
          4. Bio-ADM concentration &gt; 70 pg/ml&#xD;
&#xD;
          5. Patient with early septic shock (start of vasopressor therapy &lt; 12 hours)&#xD;
&#xD;
          6. Women of childbearing potential must have a negative serum or urine pregnancy test&#xD;
             before randomization&#xD;
&#xD;
          7. Highly effective method of contraception must be maintained for 6 months after study&#xD;
             start by women of childbearing potential and sexually active men.&#xD;
&#xD;
          8. No care limitation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Moribund&#xD;
&#xD;
          2. Pre-existing unstable condition (e.g. a recent cerebral hemorrhage or infarct, a&#xD;
             recent acute unstable myocardial infarction (all &lt; 3 months), congestive heart failure&#xD;
             - New York Heart Association (NYHA) Class IV&#xD;
&#xD;
          3. Patients that required cardiopulmonary resuscitation in the last 4 weeks prior to&#xD;
             evaluation for enrollment&#xD;
&#xD;
          4. Severe Chronic Obstructive Pulmonary Disease (COPD) with chronic oxygen need at home&#xD;
             (GOLD IV)&#xD;
&#xD;
          5. Any organ or bone marrow transplant within the past 24 weeks&#xD;
&#xD;
          6. Uncontrolled serious hemorrhage (≥ 2 units of blood / platelets in the previous 24&#xD;
             hrs.). Patients may be considered for enrollment if bleeding has stopped and patient&#xD;
             is otherwise qualified&#xD;
&#xD;
          7. Uncontrolled hematological / oncological malignancies&#xD;
&#xD;
          8. Absolute neutropenia &lt; 500 per µL&#xD;
&#xD;
          9. Severe chronic liver disease (Child-Pugh C)&#xD;
&#xD;
         10. Systemic fungal infection or active tuberculosis&#xD;
&#xD;
         11. Neuromuscular disorders that impact breathing / spontaneous ventilation&#xD;
&#xD;
         12. Burns &gt; 30% of body surface&#xD;
&#xD;
         13. Plasmapheresis&#xD;
&#xD;
         14. Breastfeeding women&#xD;
&#xD;
         15. Participation in a clinical trial involving another investigational drug within 4&#xD;
             weeks prior to inclusion&#xD;
&#xD;
         16. Unwilling or unable to be fully evaluated for all follow-up visits&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens Zimmermann, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Adrenomed AG</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinique Universitaire Saint-Luc (UCL Bruxelles)</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Antwerp University Hospital (UZA), Critical Care Medicine</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Jolimont, Hospitalier de Jolimont</name>
      <address>
        <city>Haine Saint Paul</city>
        <zip>7100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique St. Pierre, Intensive Care</name>
      <address>
        <city>Ottignies</city>
        <zip>1340</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Intensive Care Medicine, Centre hospital - universitaire</name>
      <address>
        <city>Angers</city>
        <state>Cedex</state>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Victor Dupouy</name>
      <address>
        <city>Argenteuil</city>
        <state>Cedex</state>
        <zip>95107</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Beaujon; Anesthesie Reanimation</name>
      <address>
        <city>Clichy</city>
        <state>Cedex</state>
        <zip>92118</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges</name>
      <address>
        <city>Limoges</city>
        <state>Cedex</state>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes; Medicine Intensive Reanimation</name>
      <address>
        <city>Nantes</city>
        <state>Cedex</state>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Bretonneau, Medecine Intensive Réanimation</name>
      <address>
        <city>Tours</city>
        <state>Cedex</state>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Clermont-Ferrand, Dept. of Perioperative Medicine</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP, Hopital Louis Mourier, Réanimation Médicale</name>
      <address>
        <city>Colombes</city>
        <zip>92700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHD-Vendée</name>
      <address>
        <city>La Roche Sur Yon</city>
        <zip>85000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de Bicêtre, Service d'anesthésie-réanimation chirurgicale</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Lariboisière, Dept. d'Anesthesie</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Lariboisière, Réanimation Médicale et Traumatologique</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Louis, Service d'Anesthésie-Réanimation</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou, Service d'Anesthésie-Réanimation Chirurgicale, Université Paris Descartes</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nouvel Hopital Civil</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de Hautepierre , Hôpitaux Universitaires de Strasbourg, Unité de Réanimation Chirurgicale, Service d'Anesthésie-Réanimation Chirurgicale</name>
      <address>
        <city>Strasbourg</city>
        <zip>67200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Aachen, Klinik für Operative Intensivmedizin</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf Klinik für Intensivmedizin</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena Klinik für Anästhesiologie und Intensivmedizin</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster Klinik für Anästhesiologie, operative Intensivmedizin und Schmerztherapie</name>
      <address>
        <city>Muenster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Rostock Klinik und Poliklinik für Anästhesiologie und Intensivtherapie</name>
      <address>
        <city>Rostock</city>
        <zip>18057</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gelderse Vallei Hospital, Department of Intensive Care</name>
      <address>
        <city>Ede</city>
        <zip>6716 RP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente, Department of Intensive Care</name>
      <address>
        <city>Enschede</city>
        <zip>7512 KZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zuyderland Medical Center, Department of Intensive Care</name>
      <address>
        <city>Heerlen</city>
        <zip>6401 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radboud UMC Intensive Care</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Canisius-Wilhelmina-Ziekenhuis (CWZ), Intensive Care</name>
      <address>
        <city>Nijmegen</city>
        <zip>6532 SZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 22, 2017</study_first_submitted>
  <study_first_submitted_qc>March 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2017</study_first_posted>
  <results_first_submitted>December 17, 2020</results_first_submitted>
  <results_first_submitted_qc>March 1, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 24, 2021</results_first_posted>
  <last_update_submitted>March 1, 2021</last_update_submitted>
  <last_update_submitted_qc>March 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Early Septic Shock</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 28, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/58/NCT03085758/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 5, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/58/NCT03085758/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First patient enrolled: 08-Dec-2017 Last patient completed: 20-Dec-2019 Total study duration: 25 months</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment Arm A</title>
          <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 2 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 2 mg/kg</description>
        </group>
        <group group_id="P2">
          <title>Treatment Arm B</title>
          <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 4 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 4 mg/kg</description>
        </group>
        <group group_id="P3">
          <title>Control Group</title>
          <description>Intravenous infusion over approximately 1 hour of single i.v. dose of Placebo of Adrecizumab&#xD;
Placebo: Single i.v. dose of placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="72"/>
                <participants group_id="P2" count="77"/>
                <participants group_id="P3" count="152"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="49"/>
                <participants group_id="P3" count="96"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="56"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="53"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refusal to recall it up to day 90</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pt seen by doctor in digestive surgery</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment Arm A</title>
          <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 2 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 2 mg/kg</description>
        </group>
        <group group_id="B2">
          <title>Treatment Arm B</title>
          <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 4 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 4 mg/kg</description>
        </group>
        <group group_id="B3">
          <title>Control Group</title>
          <description>Intravenous infusion over approximately 1 hour of single i.v. dose of Placebo of Adrecizumab&#xD;
Placebo: Single i.v. dose of placebo</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="72"/>
            <count group_id="B2" value="77"/>
            <count group_id="B3" value="152"/>
            <count group_id="B4" value="301"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="72"/>
                    <count group_id="B2" value="77"/>
                    <count group_id="B3" value="152"/>
                    <count group_id="B4" value="301"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.2" lower_limit="30" upper_limit="94"/>
                    <measurement group_id="B2" value="68.8" lower_limit="18" upper_limit="89"/>
                    <measurement group_id="B3" value="69.3" lower_limit="21" upper_limit="94"/>
                    <measurement group_id="B4" value="68.4" lower_limit="18" upper_limit="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="72"/>
                    <count group_id="B2" value="77"/>
                    <count group_id="B3" value="152"/>
                    <count group_id="B4" value="301"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="66"/>
                    <measurement group_id="B4" value="117"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="86"/>
                    <measurement group_id="B4" value="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="72"/>
                    <count group_id="B2" value="77"/>
                    <count group_id="B3" value="152"/>
                    <count group_id="B4" value="301"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="72"/>
                    <count group_id="B2" value="77"/>
                    <count group_id="B3" value="152"/>
                    <count group_id="B4" value="301"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="72"/>
                    <count group_id="B2" value="77"/>
                    <count group_id="B3" value="152"/>
                    <count group_id="B4" value="301"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="107"/>
                    <measurement group_id="B4" value="221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="72"/>
                    <count group_id="B2" value="77"/>
                    <count group_id="B3" value="152"/>
                    <count group_id="B4" value="301"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not reported</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="72"/>
                    <count group_id="B2" value="77"/>
                    <count group_id="B3" value="152"/>
                    <count group_id="B4" value="301"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Netherlands</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="72"/>
                    <count group_id="B2" value="77"/>
                    <count group_id="B3" value="152"/>
                    <count group_id="B4" value="301"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="72"/>
                    <count group_id="B2" value="77"/>
                    <count group_id="B3" value="152"/>
                    <count group_id="B4" value="301"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="72"/>
                    <count group_id="B2" value="77"/>
                    <count group_id="B3" value="152"/>
                    <count group_id="B4" value="301"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="64"/>
                    <measurement group_id="B4" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="72"/>
                    <count group_id="B2" value="77"/>
                    <count group_id="B3" value="152"/>
                    <count group_id="B4" value="301"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Location before ICU admission</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Home</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="72"/>
                    <count group_id="B2" value="77"/>
                    <count group_id="B3" value="152"/>
                    <count group_id="B4" value="301"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospital</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="72"/>
                    <count group_id="B2" value="77"/>
                    <count group_id="B3" value="152"/>
                    <count group_id="B4" value="301"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="144"/>
                    <measurement group_id="B4" value="277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Origin of sepsis</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Peritonitis</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="72"/>
                    <count group_id="B2" value="77"/>
                    <count group_id="B3" value="152"/>
                    <count group_id="B4" value="301"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lung</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="72"/>
                    <count group_id="B2" value="77"/>
                    <count group_id="B3" value="152"/>
                    <count group_id="B4" value="301"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urinary tract</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="72"/>
                    <count group_id="B2" value="77"/>
                    <count group_id="B3" value="152"/>
                    <count group_id="B4" value="301"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin and soft tissue</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="72"/>
                    <count group_id="B2" value="77"/>
                    <count group_id="B3" value="152"/>
                    <count group_id="B4" value="301"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bile duct infection</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="72"/>
                    <count group_id="B2" value="77"/>
                    <count group_id="B3" value="152"/>
                    <count group_id="B4" value="301"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood stream</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="72"/>
                    <count group_id="B2" value="77"/>
                    <count group_id="B3" value="152"/>
                    <count group_id="B4" value="301"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Central nervous system</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="72"/>
                    <count group_id="B2" value="77"/>
                    <count group_id="B3" value="152"/>
                    <count group_id="B4" value="301"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Catheter</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="72"/>
                    <count group_id="B2" value="77"/>
                    <count group_id="B3" value="152"/>
                    <count group_id="B4" value="301"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="72"/>
                    <count group_id="B2" value="77"/>
                    <count group_id="B3" value="152"/>
                    <count group_id="B4" value="301"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <population>Treatment group A Row population differs from the Overall because height was not determined for one subject, therefore, no BMI was calculated.&#xD;
Treatment group C Row population differs from the Overall because height was not determined for one subject, therefore, no BMI was calculated.</population>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="71"/>
                    <count group_id="B2" value="77"/>
                    <count group_id="B3" value="151"/>
                    <count group_id="B4" value="299"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.41" lower_limit="16.7" upper_limit="45.7"/>
                    <measurement group_id="B2" value="26.72" lower_limit="17.0" upper_limit="43.3"/>
                    <measurement group_id="B3" value="27.78" lower_limit="14.1" upper_limit="45.5"/>
                    <measurement group_id="B4" value="27.18" lower_limit="14.1" upper_limit="45.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body temperature</title>
          <population>Treatment group A Row population differs from the Overall because body temperature was not done for 6 subjects.&#xD;
Treatment group B Row population differs from the Overall because body temperature was not done for 4 subjects.&#xD;
Treatment group C Row population differs from the Overall because body temperature was not done for 7 subjects.</population>
          <units>degrees C</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="66"/>
                    <count group_id="B2" value="73"/>
                    <count group_id="B3" value="145"/>
                    <count group_id="B4" value="284"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.06" lower_limit="34.6" upper_limit="39.9"/>
                    <measurement group_id="B2" value="36.97" lower_limit="33.4" upper_limit="39.9"/>
                    <measurement group_id="B3" value="37.08" lower_limit="33.8" upper_limit="40.5"/>
                    <measurement group_id="B4" value="37.05" lower_limit="33.4" upper_limit="40.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Heart rate</title>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="72"/>
                    <count group_id="B2" value="77"/>
                    <count group_id="B3" value="152"/>
                    <count group_id="B4" value="301"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="104.38" lower_limit="51.0" upper_limit="158.0"/>
                    <measurement group_id="B2" value="97.40" lower_limit="60.0" upper_limit="151.0"/>
                    <measurement group_id="B3" value="96.37" lower_limit="44.0" upper_limit="153.0"/>
                    <measurement group_id="B4" value="98.55" lower_limit="44.0" upper_limit="158.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean arterial pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="72"/>
                    <count group_id="B2" value="77"/>
                    <count group_id="B3" value="152"/>
                    <count group_id="B4" value="301"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.18" lower_limit="43.0" upper_limit="99.0"/>
                    <measurement group_id="B2" value="71.35" lower_limit="32.0" upper_limit="104.0"/>
                    <measurement group_id="B3" value="72.49" lower_limit="22.0" upper_limit="110.0"/>
                    <measurement group_id="B4" value="72.36" lower_limit="22.0" upper_limit="110.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Respiratory rate</title>
          <population>Treatment group A Row population differs from the Overall because respiratory rate was not done for 2 subjects&#xD;
Treatment group C Row population differs from the Overall because respiratory rate was not done for 3 subjects</population>
          <units>breaths/min</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="70"/>
                    <count group_id="B2" value="77"/>
                    <count group_id="B3" value="149"/>
                    <count group_id="B4" value="296"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.63" lower_limit="8.0" upper_limit="44.0"/>
                    <measurement group_id="B2" value="21.90" lower_limit="10.0" upper_limit="37.0"/>
                    <measurement group_id="B3" value="21.96" lower_limit="8.0" upper_limit="36.0"/>
                    <measurement group_id="B4" value="22.34" lower_limit="8.0" upper_limit="44.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Bio-ADM</title>
          <description>bio-ADM measures the plasma level of the biological active Adrenomedullin, a vasoactive hormone that regulates blood pressure and vascular integrity&#xD;
Note results characterized as &quot;3000&quot; are to be read as &gt;3000</description>
          <units>pg/mL (local)</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="72"/>
                    <count group_id="B2" value="77"/>
                    <count group_id="B3" value="152"/>
                    <count group_id="B4" value="301"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="284.30" lower_limit="74.9" upper_limit="1967.1"/>
                    <measurement group_id="B2" value="305.15" lower_limit="74.6" upper_limit="2328.9"/>
                    <measurement group_id="B3" value="755.92" lower_limit="74.3" upper_limit="3000"/>
                    <measurement group_id="B4" value="527.80" lower_limit="74.3" upper_limit="3000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Blood lactate</title>
          <population>Treatment group A Row population differs from the Overall because blood lactate was not done for 4 subjects Treatment group B Row population differs from the Overall because blood lactate was not done for 2 subjects Treatment group C Row population differs from the Overall because blood lactate was not done for 3 subjects</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="68"/>
                    <count group_id="B2" value="75"/>
                    <count group_id="B3" value="149"/>
                    <count group_id="B4" value="292"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.11" lower_limit="0.8" upper_limit="15.0"/>
                    <measurement group_id="B2" value="4.19" lower_limit="0.9" upper_limit="17.0"/>
                    <measurement group_id="B3" value="4.23" lower_limit="0.6" upper_limit="64.0"/>
                    <measurement group_id="B4" value="4.19" lower_limit="0.6" upper_limit="64.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Creatinine</title>
          <population>Treatment group A Row population differs from the Overall because creatinine was not done for 1 subject Treatment group B Row population differs from the Overall because creatinine was not done for 1 subject</population>
          <units>μmol/L</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="71"/>
                    <count group_id="B2" value="76"/>
                    <count group_id="B3" value="152"/>
                    <count group_id="B4" value="299"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="189.649" lower_limit="31.82" upper_limit="582.00"/>
                    <measurement group_id="B2" value="199.891" lower_limit="53.04" upper_limit="834.50"/>
                    <measurement group_id="B3" value="192.801" lower_limit="32.10" upper_limit="912.29"/>
                    <measurement group_id="B4" value="193.854" lower_limit="31.82" upper_limit="912.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Apache II Score</title>
          <description>Minimum score = 0; maximum score = 71. Increasing score is associated with increasing risk of hospital death.</description>
          <population>Treatment group A Row population differs from the Overall because Apache II Score was not done for 10 subjects Treatment group B Row population differs from the Overall because Apache II Score was not done for 11 subjects Treatment group C Row population differs from the Overall because Apache II Score was not done for 8 subjects</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="62"/>
                    <count group_id="B2" value="66"/>
                    <count group_id="B3" value="144"/>
                    <count group_id="B4" value="272"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.4" lower_limit="17" upper_limit="42"/>
                    <measurement group_id="B2" value="31.8" lower_limit="20" upper_limit="42"/>
                    <measurement group_id="B3" value="31.5" lower_limit="14" upper_limit="53"/>
                    <measurement group_id="B4" value="31.6" lower_limit="14" upper_limit="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sequential Organ Failure Assessment (SOFA) Score</title>
          <description>The Sequential Organ Failure Assessment (SOFA) Score is a mortality prediction score that is based on the degree of dysfunction of six organ systems.&#xD;
SOFA score: Minimum possible score is 0, maximum is 24. A higher score meas a worse outcome.</description>
          <population>Treatment group A Row population differs from the Overall because SOFA Score was not done for 11 subjects Treatment group B Row population differs from the Overall because SOFA Score was not done for 16 subjects Treatment group C Row population differs from the Overall because SOFA Score was not done for 20 subjects</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="61"/>
                    <count group_id="B2" value="61"/>
                    <count group_id="B3" value="132"/>
                    <count group_id="B4" value="254"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.1" lower_limit="4" upper_limit="17"/>
                    <measurement group_id="B2" value="10.0" lower_limit="5" upper_limit="16"/>
                    <measurement group_id="B3" value="9.6" lower_limit="4" upper_limit="16"/>
                    <measurement group_id="B4" value="9.9" lower_limit="4" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Endpoints for Primary Objective (Safety and Tolerability of Adrecizumab: Mortality)</title>
        <description>The endpoints for the primary objective is mortality evaluated over the 90 days study period.</description>
        <time_frame>90 days</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 2 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 2 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 4 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 4 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Adrecizumab Overall</title>
            <description>Treatment Arm A and Treatment Arm B combined</description>
          </group>
          <group group_id="O4">
            <title>Control Group</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of Placebo of Adrecizumab&#xD;
Placebo: Single i.v. dose of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Endpoints for Primary Objective (Safety and Tolerability of Adrecizumab: Mortality)</title>
          <description>The endpoints for the primary objective is mortality evaluated over the 90 days study period.</description>
          <population>Full Analysis Set</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="149"/>
                <count group_id="O4" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.1453" spread="4.0940"/>
                    <measurement group_id="O2" value="63.1578" spread="3.5967"/>
                    <measurement group_id="O3" value="64.5744" spread="2.7582"/>
                    <measurement group_id="O4" value="63.9809" spread="2.9466"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Endpoints for Primary Objective (Safety and Tolerability of Adrecizumab: Interruption of Infusion)</title>
        <description>The endpoints for the primary objective are to determine over the 90 days study period: Interruption of infusion due to intolerability of ADRECIZUMAB</description>
        <time_frame>90 days</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 2 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 2 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 4 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 4 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Adrecizumab Overall</title>
            <description>Treatment Arm A and Treatment Arm B combined</description>
          </group>
          <group group_id="O4">
            <title>Control Group</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of Placebo of Adrecizumab&#xD;
Placebo: Single i.v. dose of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Endpoints for Primary Objective (Safety and Tolerability of Adrecizumab: Interruption of Infusion)</title>
          <description>The endpoints for the primary objective are to determine over the 90 days study period: Interruption of infusion due to intolerability of ADRECIZUMAB</description>
          <population>Safety Analysis Set</population>
          <units>Interruptions</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="149"/>
                <count group_id="O4" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Endpoints for Primary Objective (Safety and Tolerability of Adrecizumab: Frequency of TEAEs)</title>
        <description>The endpoints for the primary objective are to determine over the 90 days study period. Number of participants with treatment-emergent adverse events per treatment group.</description>
        <time_frame>90 days</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 2 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 2 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 4 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 4 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Adrecizumab Overall</title>
            <description>Treatment Arm A and Treatment Arm B combined</description>
          </group>
          <group group_id="O4">
            <title>Control Group</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of Placebo of Adrecizumab&#xD;
Placebo: Single i.v. dose of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Endpoints for Primary Objective (Safety and Tolerability of Adrecizumab: Frequency of TEAEs)</title>
          <description>The endpoints for the primary objective are to determine over the 90 days study period. Number of participants with treatment-emergent adverse events per treatment group.</description>
          <population>Safety Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="149"/>
                <count group_id="O4" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="74"/>
                    <measurement group_id="O3" value="142"/>
                    <measurement group_id="O4" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy to be Determined by Sepsis Support Index (SSI)</title>
        <description>The primary efficacy endpoint of this study is the Sepsis Support Index (SSI) defined as: days with organ support or dead within 14 day follow up More precisely: In the time frame of 14 day follow-up, each day on support with vasopressor, and/or mechanical ventilation, and/or renal dysfunction (defined as renal SOFA = 4), or not alive, is counted as 1. The sum over the follow up period is defined as SSI.&#xD;
Minimum value possible is 0, maximum value is 14. A higher score means a worse outcome.</description>
        <time_frame>14 days</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 2 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 2 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 4 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 4 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Adrecizumab Overall</title>
            <description>Treatment Arm A and Treatment Arm B combined</description>
          </group>
          <group group_id="O4">
            <title>Control Group</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of Placebo of Adrecizumab&#xD;
Placebo: Single i.v. dose of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy to be Determined by Sepsis Support Index (SSI)</title>
          <description>The primary efficacy endpoint of this study is the Sepsis Support Index (SSI) defined as: days with organ support or dead within 14 day follow up More precisely: In the time frame of 14 day follow-up, each day on support with vasopressor, and/or mechanical ventilation, and/or renal dysfunction (defined as renal SOFA = 4), or not alive, is counted as 1. The sum over the follow up period is defined as SSI.&#xD;
Minimum value possible is 0, maximum value is 14. A higher score means a worse outcome.</description>
          <population>Full Analysis Set</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="146"/>
                <count group_id="O4" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4" spread="5.16"/>
                    <measurement group_id="O2" value="9.1" spread="5.20"/>
                    <measurement group_id="O3" value="8.8" spread="5.18"/>
                    <measurement group_id="O4" value="8.1" spread="5.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sepsis Support Index (SSI)</title>
        <description>Sepsis Support Index (SSI) at 28 day follow-up Minimum value possible is 0, maximum value is 14. A higher score means a worse outcome.</description>
        <time_frame>28 days</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 2 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 2 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 4 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 4 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Adrecizumab Overall</title>
            <description>Treatment Arm A and Treatment Arm B combined</description>
          </group>
          <group group_id="O4">
            <title>Control Group</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of Placebo of Adrecizumab&#xD;
Placebo: Single i.v. dose of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Sepsis Support Index (SSI)</title>
          <description>Sepsis Support Index (SSI) at 28 day follow-up Minimum value possible is 0, maximum value is 14. A higher score means a worse outcome.</description>
          <population>Full Analysis Set</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="145"/>
                <count group_id="O4" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3" spread="10.91"/>
                    <measurement group_id="O2" value="14.6" spread="10.76"/>
                    <measurement group_id="O3" value="14.0" spread="10.82"/>
                    <measurement group_id="O4" value="12.8" spread="11.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Penalized Sepsis Support Index (pSSI) at 14 Day Follow-up</title>
        <description>Penalized Sepsis Support Index (pSSI) at day 14, defined similar to the SSI with the exception that patients that die get penalized by assigning the maximum value, i.e. the pSSI is set to 14 or 28, respectively.&#xD;
Minimum value possible is 0, maximum value is 14. A higher score means a worse outcome.</description>
        <time_frame>day 14</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 2 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 2 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 4 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 4 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Adrecizumab Overall</title>
            <description>Treatment Arm A and Treatment Arm B combined</description>
          </group>
          <group group_id="O4">
            <title>Control Group</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of Placebo of Adrecizumab&#xD;
Placebo: Single i.v. dose of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Penalized Sepsis Support Index (pSSI) at 14 Day Follow-up</title>
          <description>Penalized Sepsis Support Index (pSSI) at day 14, defined similar to the SSI with the exception that patients that die get penalized by assigning the maximum value, i.e. the pSSI is set to 14 or 28, respectively.&#xD;
Minimum value possible is 0, maximum value is 14. A higher score means a worse outcome.</description>
          <population>Full Analysis Set</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="146"/>
                <count group_id="O4" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" spread="5.26"/>
                    <measurement group_id="O2" value="9.1" spread="5.20"/>
                    <measurement group_id="O3" value="8.8" spread="5.22"/>
                    <measurement group_id="O4" value="8.1" spread="5.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Persistent Organ Dysfunction or Death at 14 and 28 Day Follow-up</title>
        <description>Persistent organ dysfunction or death at 14 and 28 day follow-up. Count of participants with either persistent organ dysfunction or death at Day 14 and Day 28. Persistent Organ Dysfunction is defined as the persistence of organ dysfunction requiring supportive technologies during the convalescent phase of critical illness and it is present when a patient has an ongoing requirement for vasopressors, dialysis, or mechanical ventilation at the outcome assessments time points, as defined by Heyland et al.; Persistent organ dysfunction plus death: a novel,composite outcome measure for critical care trials. Critical Care 2011, 15.</description>
        <time_frame>day 14 and day 28</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 2 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 2 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 4 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 4 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Adrecizumab Overall</title>
            <description>Treatment Arm A and Treatment Arm B combined</description>
          </group>
          <group group_id="O4">
            <title>Control Group</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of Placebo of Adrecizumab&#xD;
Placebo: Single i.v. dose of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Persistent Organ Dysfunction or Death at 14 and 28 Day Follow-up</title>
          <description>Persistent organ dysfunction or death at 14 and 28 day follow-up. Count of participants with either persistent organ dysfunction or death at Day 14 and Day 28. Persistent Organ Dysfunction is defined as the persistence of organ dysfunction requiring supportive technologies during the convalescent phase of critical illness and it is present when a patient has an ongoing requirement for vasopressors, dialysis, or mechanical ventilation at the outcome assessments time points, as defined by Heyland et al.; Persistent organ dysfunction plus death: a novel,composite outcome measure for critical care trials. Critical Care 2011, 15.</description>
          <population>Full Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="149"/>
                <count group_id="O4" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="66"/>
                    <measurement group_id="O4" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="50"/>
                    <measurement group_id="O4" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mortality Rate</title>
        <description>Day 28 mortality rate</description>
        <time_frame>day 28</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 2 mg/kg Adrecizumab Adrecizumab: Single i.v. dose of 2 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 4 mg/kg Adrecizumab Adrecizumab: Single i.v. dose of 4 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Adrecizumab Overall</title>
            <description>Treatment Group A and Treatment Group B combined</description>
          </group>
          <group group_id="O4">
            <title>Control Group</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of Placebo of Adrecizumab&#xD;
Placebo: Single i.v. dose of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality Rate</title>
          <description>Day 28 mortality rate</description>
          <population>Full Analysis Set</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="149"/>
                <count group_id="O4" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.3484" spread="0.8694"/>
                    <measurement group_id="O2" value="17.5630" spread="0.6592"/>
                    <measurement group_id="O3" value="20.5162" spread="0.5903"/>
                    <measurement group_id="O4" value="22.8783" spread="0.7627"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SSI and pSSI Excluding the Renal Component</title>
        <description>Sepsis Support Index (SSI) and penalized Sepsis Support Index (pSSI) excluding the renal component. pSSI is a version of the SSI where mortality is given extra weight: Patients being alive during the 14 days' follow up will have an SSI ranging up to 14, while patients who died within that period will be assigned a score of &quot;14 plus the number of days not being alive&quot;. Thus the SSI and pSSI score may range between zero and 28. A higher score means a worse outcome. The number of participants analyzed differs per row due to missing data.</description>
        <time_frame>day 14 and day 28</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 2 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 2 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 4 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 4 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Adrecizumab Overall</title>
            <description>Treatment Arm A and Treatment Arm B combined</description>
          </group>
          <group group_id="O4">
            <title>Control Group</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of Placebo of Adrecizumab&#xD;
Placebo: Single i.v. dose of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>SSI and pSSI Excluding the Renal Component</title>
          <description>Sepsis Support Index (SSI) and penalized Sepsis Support Index (pSSI) excluding the renal component. pSSI is a version of the SSI where mortality is given extra weight: Patients being alive during the 14 days' follow up will have an SSI ranging up to 14, while patients who died within that period will be assigned a score of &quot;14 plus the number of days not being alive&quot;. Thus the SSI and pSSI score may range between zero and 28. A higher score means a worse outcome. The number of participants analyzed differs per row due to missing data.</description>
          <population>Full Analysis Set</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="146"/>
                <count group_id="O4" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SSI Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="146"/>
                    <count group_id="O4" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" spread="5.21"/>
                    <measurement group_id="O2" value="9.0" spread="5.24"/>
                    <measurement group_id="O3" value="8.5" spread="5.24"/>
                    <measurement group_id="O4" value="7.9" spread="5.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SSI Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="146"/>
                    <count group_id="O4" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.9" spread="11.03"/>
                    <measurement group_id="O2" value="14.3" spread="10.80"/>
                    <measurement group_id="O3" value="13.6" spread="10.90"/>
                    <measurement group_id="O4" value="12.6" spread="11.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pSSI Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="146"/>
                    <count group_id="O4" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" spread="5.32"/>
                    <measurement group_id="O2" value="9.0" spread="5.24"/>
                    <measurement group_id="O3" value="8.6" spread="5.28"/>
                    <measurement group_id="O4" value="7.9" spread="5.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pSSI Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="146"/>
                    <count group_id="O4" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.4" spread="11.47"/>
                    <measurement group_id="O2" value="14.5" spread="10.92"/>
                    <measurement group_id="O3" value="14.0" spread="11.17"/>
                    <measurement group_id="O4" value="12.9" spread="11.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SSI Weighted for Mortality</title>
        <description>Sepsis Support Index (SSI) Weighted for Mortality. Minimum value possible is 0, maximum value is 14. A higher score means a worse outcome.</description>
        <time_frame>day 14</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 2 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 2 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 4 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 4 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Adrecizumab Overall</title>
            <description>Treatment Arm A and Treatment Arm B combined</description>
          </group>
          <group group_id="O4">
            <title>Control Group</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of Placebo of Adrecizumab&#xD;
Placebo: Single i.v. dose of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>SSI Weighted for Mortality</title>
          <description>Sepsis Support Index (SSI) Weighted for Mortality. Minimum value possible is 0, maximum value is 14. A higher score means a worse outcome.</description>
          <population>Full Analysis Set</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="146"/>
                <count group_id="O4" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2" spread="7.76"/>
                    <measurement group_id="O2" value="10.7" spread="7.65"/>
                    <measurement group_id="O3" value="10.5" spread="7.68"/>
                    <measurement group_id="O4" value="9.9" spread="8.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Individual Sepsis Support Index Components</title>
        <description>Individual Sepsis Support Index (SSI) components (hemodynamic, respiratory and renal failure) with and without mortality.&#xD;
Minimum value possible is 0, maximum value is 14. A higher score means a worse outcome. The number of participants analyzed differs per row due to missing data.</description>
        <time_frame>day 14 and day 28</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 2 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 2 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 4 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 4 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Adrecizumab Overall</title>
            <description>Treatment Arm A and Treatment Arm B combined</description>
          </group>
          <group group_id="O4">
            <title>Control Group</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of Placebo of Adrecizumab&#xD;
Placebo: Single i.v. dose of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Individual Sepsis Support Index Components</title>
          <description>Individual Sepsis Support Index (SSI) components (hemodynamic, respiratory and renal failure) with and without mortality.&#xD;
Minimum value possible is 0, maximum value is 14. A higher score means a worse outcome. The number of participants analyzed differs per row due to missing data.</description>
          <population>Full Analysis Set</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="149"/>
                <count group_id="O4" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SSI cardiac component day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="64"/>
                    <count group_id="O3" value="121"/>
                    <count group_id="O4" value="119"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="2.95"/>
                    <measurement group_id="O2" value="5.4" spread="4.01"/>
                    <measurement group_id="O3" value="4.7" spread="3.60"/>
                    <measurement group_id="O4" value="4.6" spread="3.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SSI cardiac component day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="58"/>
                    <count group_id="O3" value="111"/>
                    <count group_id="O4" value="109"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="5.03"/>
                    <measurement group_id="O2" value="5.8" spread="5.61"/>
                    <measurement group_id="O3" value="5.3" spread="5.35"/>
                    <measurement group_id="O4" value="4.7" spread="4.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SSI respiratory component day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="64"/>
                    <count group_id="O3" value="121"/>
                    <count group_id="O4" value="119"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" spread="5.41"/>
                    <measurement group_id="O2" value="7.3" spread="5.98"/>
                    <measurement group_id="O3" value="6.4" spread="5.78"/>
                    <measurement group_id="O4" value="5.1" spread="5.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SSI respiratory component day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="58"/>
                    <count group_id="O3" value="111"/>
                    <count group_id="O4" value="109"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" spread="9.14"/>
                    <measurement group_id="O2" value="9.6" spread="9.85"/>
                    <measurement group_id="O3" value="8.3" spread="9.57"/>
                    <measurement group_id="O4" value="5.8" spread="8.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SSI renal failure component day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="64"/>
                    <count group_id="O3" value="121"/>
                    <count group_id="O4" value="119"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="3.55"/>
                    <measurement group_id="O2" value="1.5" spread="3.27"/>
                    <measurement group_id="O3" value="1.4" spread="3.39"/>
                    <measurement group_id="O4" value="1.4" spread="3.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SSI renal failure component day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="58"/>
                    <count group_id="O3" value="110"/>
                    <count group_id="O4" value="107"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="5.30"/>
                    <measurement group_id="O2" value="1.9" spread="4.63"/>
                    <measurement group_id="O3" value="1.9" spread="4.93"/>
                    <measurement group_id="O4" value="1.4" spread="3.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SSI death component day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="146"/>
                    <count group_id="O4" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="3.86"/>
                    <measurement group_id="O2" value="1.6" spread="4.02"/>
                    <measurement group_id="O3" value="1.6" spread="3.93"/>
                    <measurement group_id="O4" value="2.0" spread="4.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SSI death component day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="146"/>
                    <count group_id="O4" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="9.23"/>
                    <measurement group_id="O2" value="4.5" spread="9.07"/>
                    <measurement group_id="O3" value="4.7" spread="9.12"/>
                    <measurement group_id="O4" value="5.5" spread="9.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sequential Organ Failure Assessment (SOFA) Score : Composite Measure: SOFA Score and Its Changes Over Time</title>
        <description>Sequential Organ Failure Assessment (SOFA) Score:&#xD;
SOFA score change at Day 3 - baseline, delta = difference between maximum and minimum score during ICU stay, mean/maximum/total daily score during ICU stay, SOFA-3 (score limited to cardiovascular, respiratory and renal function). Measured at baseline and Day 3.&#xD;
SOFA score: Minimum possible score is 0, maximum is 24. A higher score meas a worse outcome. Measured at baseline, Day 2 to Day 28.&#xD;
SOFA-3 score: Minimum possible score is 0, maximum is 12. A higher score meas a worse outcome. Measured at baseline, Day 2 to Day 28.</description>
        <time_frame>28 days</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 2 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 2 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 4 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 4 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Adrecizumab Overall</title>
            <description>Treatment Arm A and Treatment Arm B combined</description>
          </group>
          <group group_id="O4">
            <title>Control Group</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of Placebo of Adrecizumab&#xD;
Placebo: Single i.v. dose of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Sequential Organ Failure Assessment (SOFA) Score : Composite Measure: SOFA Score and Its Changes Over Time</title>
          <description>Sequential Organ Failure Assessment (SOFA) Score:&#xD;
SOFA score change at Day 3 - baseline, delta = difference between maximum and minimum score during ICU stay, mean/maximum/total daily score during ICU stay, SOFA-3 (score limited to cardiovascular, respiratory and renal function). Measured at baseline and Day 3.&#xD;
SOFA score: Minimum possible score is 0, maximum is 24. A higher score meas a worse outcome. Measured at baseline, Day 2 to Day 28.&#xD;
SOFA-3 score: Minimum possible score is 0, maximum is 12. A higher score meas a worse outcome. Measured at baseline, Day 2 to Day 28.</description>
          <population>Full Analysis Set</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="149"/>
                <count group_id="O4" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SOFA change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="112"/>
                    <count group_id="O4" value="116"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="4.77"/>
                    <measurement group_id="O2" value="-0.2" spread="4.87"/>
                    <measurement group_id="O3" value="-0.5" spread="4.87"/>
                    <measurement group_id="O4" value="0.3" spread="5.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SOFA Delta score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="66"/>
                    <count group_id="O2" value="70"/>
                    <count group_id="O3" value="136"/>
                    <count group_id="O4" value="137"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="2.50"/>
                    <measurement group_id="O2" value="4.8" spread="3.80"/>
                    <measurement group_id="O3" value="4.5" spread="3.24"/>
                    <measurement group_id="O4" value="3.8" spread="3.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SOFA maximum score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="66"/>
                    <count group_id="O2" value="70"/>
                    <count group_id="O3" value="136"/>
                    <count group_id="O4" value="137"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2" spread="3.77"/>
                    <measurement group_id="O2" value="10.8" spread="4.46"/>
                    <measurement group_id="O3" value="10.5" spread="4.13"/>
                    <measurement group_id="O4" value="9.7" spread="3.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SOFA mean score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="66"/>
                    <count group_id="O2" value="70"/>
                    <count group_id="O3" value="136"/>
                    <count group_id="O4" value="137"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.957" spread="3.7546"/>
                    <measurement group_id="O2" value="8.319" spread="3.8129"/>
                    <measurement group_id="O3" value="8.143" spread="3.7751"/>
                    <measurement group_id="O4" value="7.644" spread="3.5105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SOFA total score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="66"/>
                    <count group_id="O2" value="70"/>
                    <count group_id="O3" value="136"/>
                    <count group_id="O4" value="137"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.9" spread="33.69"/>
                    <measurement group_id="O2" value="54.9" spread="55.56"/>
                    <measurement group_id="O3" value="47.1" spread="46.78"/>
                    <measurement group_id="O4" value="44.1" spread="48.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SOFA-3 change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="132"/>
                    <count group_id="O4" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="2.77"/>
                    <measurement group_id="O2" value="-0.9" spread="2.81"/>
                    <measurement group_id="O3" value="-1.3" spread="2.80"/>
                    <measurement group_id="O4" value="-0.9" spread="2.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SOFA-3 Delta score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="66"/>
                    <count group_id="O2" value="70"/>
                    <count group_id="O3" value="136"/>
                    <count group_id="O4" value="137"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="1.96"/>
                    <measurement group_id="O2" value="3.5" spread="2.26"/>
                    <measurement group_id="O3" value="3.5" spread="2.11"/>
                    <measurement group_id="O4" value="3.1" spread="2.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SOFA-3 maximum score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="66"/>
                    <count group_id="O2" value="70"/>
                    <count group_id="O3" value="136"/>
                    <count group_id="O4" value="137"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" spread="2.14"/>
                    <measurement group_id="O2" value="7.2" spread="2.60"/>
                    <measurement group_id="O3" value="7.2" spread="2.38"/>
                    <measurement group_id="O4" value="6.8" spread="2.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SOFA-3 mean score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="66"/>
                    <count group_id="O2" value="70"/>
                    <count group_id="O3" value="136"/>
                    <count group_id="O4" value="137"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.909" spread="6.5681"/>
                    <measurement group_id="O2" value="9.336" spread="7.2622"/>
                    <measurement group_id="O3" value="9.129" spread="6.9118"/>
                    <measurement group_id="O4" value="8.311" spread="8.0551"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SOFA-3 total score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="66"/>
                    <count group_id="O2" value="73"/>
                    <count group_id="O3" value="139"/>
                    <count group_id="O4" value="139"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.2" spread="42.36"/>
                    <measurement group_id="O2" value="56.4" spread="51.13"/>
                    <measurement group_id="O3" value="50.6" spread="47.40"/>
                    <measurement group_id="O4" value="44.3" spread="46.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Renal Function (Creatinine)</title>
        <description>Change in renal function as change in creatinine (day 3 - day 1, day 7 - day 1)</description>
        <time_frame>day 1, day 3 and day 7</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 2 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 2 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 4 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 4 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Adrecizumab Overall</title>
            <description>Treatment Arm A and Treatment Arm B combined</description>
          </group>
          <group group_id="O4">
            <title>Control Group</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of Placebo of Adrecizumab&#xD;
Placebo: Single i.v. dose of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Renal Function (Creatinine)</title>
          <description>Change in renal function as change in creatinine (day 3 - day 1, day 7 - day 1)</description>
          <population>Full Analysis Set</population>
          <units>μmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="145"/>
                <count group_id="O4" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>creatinine change baseline to day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="145"/>
                    <count group_id="O4" value="150"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.9" spread="85.65"/>
                    <measurement group_id="O2" value="-11.7" spread="77.99"/>
                    <measurement group_id="O3" value="-27.9" spread="85.65"/>
                    <measurement group_id="O4" value="-25.6" spread="109.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>creatinine change baseline to day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="145"/>
                    <count group_id="O4" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-46.6" spread="140.38"/>
                    <measurement group_id="O2" value="-44.9" spread="98.44"/>
                    <measurement group_id="O3" value="-45.7" spread="120.10"/>
                    <measurement group_id="O4" value="-50.5" spread="125.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Stay at ICU/ Hospital</title>
        <description>Duration of stay at ICU / hospital. The number of participants analyzed differs per row due to missing data.</description>
        <time_frame>90 days</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 2 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 2 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 4 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 4 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Adrecizumab Overall</title>
            <description>Treatment Arm A and Treatment Arm B combined</description>
          </group>
          <group group_id="O4">
            <title>Control Group</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of Placebo of Adrecizumab&#xD;
Placebo: Single i.v. dose of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Stay at ICU/ Hospital</title>
          <description>Duration of stay at ICU / hospital. The number of participants analyzed differs per row due to missing data.</description>
          <population>Full Analysis Set</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="149"/>
                <count group_id="O4" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Duration of hospital stay</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="86"/>
                    <count group_id="O4" value="95"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.3" spread="11.87"/>
                    <measurement group_id="O2" value="13.4" spread="7.71"/>
                    <measurement group_id="O3" value="12.8" spread="10.2"/>
                    <measurement group_id="O4" value="11.2" spread="7.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration of ICU stay</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="149"/>
                    <count group_id="O4" value="99"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6" spread="6.27"/>
                    <measurement group_id="O2" value="11.0" spread="7.26"/>
                    <measurement group_id="O3" value="10.3" spread="6.77"/>
                    <measurement group_id="O4" value="9.3" spread="7.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes of Functional Parameter Mean Arterial Pressure During Stay at ICU</title>
        <description>Changes of Mean Arterial Pressure (MAP). Change from baseline to day 28/last day in ICU was calculated (value at day 28 or last collected value minus value at baseline). MAP was collected at screening and daily from day 1 to day 28 or discharge as well as on the follow-up visit day 28. Vital signs were assessed as min/max values within 24 hours except at screening and on the follow-up visit day 28.</description>
        <time_frame>28 days</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 2 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 2 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 4 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 4 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Adrecizumab Overall</title>
            <description>Treatment Arm A and Treatment Arm B combined</description>
          </group>
          <group group_id="O4">
            <title>Control Group</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of Placebo of Adrecizumab&#xD;
Placebo: Single i.v. dose of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes of Functional Parameter Mean Arterial Pressure During Stay at ICU</title>
          <description>Changes of Mean Arterial Pressure (MAP). Change from baseline to day 28/last day in ICU was calculated (value at day 28 or last collected value minus value at baseline). MAP was collected at screening and daily from day 1 to day 28 or discharge as well as on the follow-up visit day 28. Vital signs were assessed as min/max values within 24 hours except at screening and on the follow-up visit day 28.</description>
          <population>Full Analysis Set</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="149"/>
                <count group_id="O4" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline (minimum)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.2" spread="21.36"/>
                    <measurement group_id="O2" value="-6.2" spread="18.44"/>
                    <measurement group_id="O3" value="-6.7" spread="19.84"/>
                    <measurement group_id="O4" value="-6.4" spread="23.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline (maximum)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.9" spread="23.64"/>
                    <measurement group_id="O2" value="17.9" spread="19.73"/>
                    <measurement group_id="O3" value="18.4" spread="21.64"/>
                    <measurement group_id="O4" value="20.2" spread="21.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes of Functional Parameter Creatinine During Stay at ICU</title>
        <description>Changes of creatinine. Measurement for baseline and Day 28 given. Creatinine was measured in the daily blood sample during ICU stay until discharge or Day 28 in a local laboratory assessment.</description>
        <time_frame>28 days</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 2 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 2 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 4 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 4 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Adrecizumab Overall</title>
            <description>Treatment Arm A and Treatment Arm B combined</description>
          </group>
          <group group_id="O4">
            <title>Control Group</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of Placebo of Adrecizumab&#xD;
Placebo: Single i.v. dose of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes of Functional Parameter Creatinine During Stay at ICU</title>
          <description>Changes of creatinine. Measurement for baseline and Day 28 given. Creatinine was measured in the daily blood sample during ICU stay until discharge or Day 28 in a local laboratory assessment.</description>
          <population>Full Analysis Set</population>
          <units>μmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="147"/>
                <count group_id="O4" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="76"/>
                    <count group_id="O3" value="147"/>
                    <count group_id="O4" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="189.649" spread="116.1689"/>
                    <measurement group_id="O2" value="199.891" spread="130.9752"/>
                    <measurement group_id="O3" value="194.944" spread="123.7293"/>
                    <measurement group_id="O4" value="192.801" spread="131.6193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.217" spread="88.1051"/>
                    <measurement group_id="O2" value="79.488" spread="65.9763"/>
                    <measurement group_id="O3" value="81.380" spread="73.3867"/>
                    <measurement group_id="O4" value="153.072" spread="120.3464"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes of Functional Parameter Partial Pressure of Oxygen in Arterial Blood(PaO2) / Fraction of Inspired Oxygen (FiO2) During Stay at ICU</title>
        <description>Changes of Partial Pressure of Oxygen in Arterial Blood (PaO2) / Fraction of inspired oxygen (FiO2) from baseline to the last observed value are measured. PaO2 and FiO2 was collected if an arterial line was in place. The arterial blood was assessed for PaO2 and FiO2. Both were measured in mmHg.</description>
        <time_frame>28 days</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 2 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 2 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 4 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 4 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Adrecizumab Overall</title>
            <description>Treatment Arm A and Treatment Arm B combined</description>
          </group>
          <group group_id="O4">
            <title>Control Group</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of Placebo of Adrecizumab&#xD;
Placebo: Single i.v. dose of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes of Functional Parameter Partial Pressure of Oxygen in Arterial Blood(PaO2) / Fraction of Inspired Oxygen (FiO2) During Stay at ICU</title>
          <description>Changes of Partial Pressure of Oxygen in Arterial Blood (PaO2) / Fraction of inspired oxygen (FiO2) from baseline to the last observed value are measured. PaO2 and FiO2 was collected if an arterial line was in place. The arterial blood was assessed for PaO2 and FiO2. Both were measured in mmHg.</description>
          <population>Full Analysis Set</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="133"/>
                <count group_id="O4" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.83" spread="155.237"/>
                    <measurement group_id="O2" value="63.80" spread="156.771"/>
                    <measurement group_id="O3" value="52.08" spread="155.896"/>
                    <measurement group_id="O4" value="15.91" spread="164.238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes of Functional Parameter Blood Lactate During Stay at ICU</title>
        <description>Changes of blood lactate from baseline to Day 28 or discharge. Blood lactate was measured in the daily blood sample from baseline to ICU discharge or until Day 28.</description>
        <time_frame>28 days</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 2 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 2 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 4 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 4 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Adrecizumab Overall</title>
            <description>Treatment Arm A and Treatment Arm B combined</description>
          </group>
          <group group_id="O4">
            <title>Control Group</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of Placebo of Adrecizumab&#xD;
Placebo: Single i.v. dose of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes of Functional Parameter Blood Lactate During Stay at ICU</title>
          <description>Changes of blood lactate from baseline to Day 28 or discharge. Blood lactate was measured in the daily blood sample from baseline to ICU discharge or until Day 28.</description>
          <population>Full Analysis Set</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="136"/>
                <count group_id="O4" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.94" spread="3.133"/>
                    <measurement group_id="O2" value="-1.54" spread="5.247"/>
                    <measurement group_id="O3" value="-1.74" spread="4.340"/>
                    <measurement group_id="O4" value="-1.49" spread="7.158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes of Functional Parameter Fluid Balance During Stay at ICU</title>
        <description>Changes of fluid balance - Last Observed Value. Percentage of Participants with low (&lt;/=1000 mL) and high (&gt;1000 mL) Fluid balance at the last observed value.&#xD;
Daily fluid intake will be calculated as the sum of all intravenous and oral fluids. The daily fluid output will be calculated as the sum of the volume of urine output, ultrafiltration fluid, drain fluid, and estimated gastrointestinal losses (including stools only in the presence of profound diarrhea). Insensitive losses will not be taken into account because they are difficult to assess reliably. Daily fluid balance (according to baseline patient weight) will be calculated by subtracting the total fluid output from the total intake.</description>
        <time_frame>28 days</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 2 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 2 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 4 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 4 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Adrecizumab Overall</title>
            <description>Treatment Arm A and Treatment Arm B combined</description>
          </group>
          <group group_id="O4">
            <title>Control Group</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of Placebo of Adrecizumab&#xD;
Placebo: Single i.v. dose of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes of Functional Parameter Fluid Balance During Stay at ICU</title>
          <description>Changes of fluid balance - Last Observed Value. Percentage of Participants with low (&lt;/=1000 mL) and high (&gt;1000 mL) Fluid balance at the last observed value.&#xD;
Daily fluid intake will be calculated as the sum of all intravenous and oral fluids. The daily fluid output will be calculated as the sum of the volume of urine output, ultrafiltration fluid, drain fluid, and estimated gastrointestinal losses (including stools only in the presence of profound diarrhea). Insensitive losses will not be taken into account because they are difficult to assess reliably. Daily fluid balance (according to baseline patient weight) will be calculated by subtracting the total fluid output from the total intake.</description>
          <population>Full Analysis Set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="149"/>
                <count group_id="O4" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.6"/>
                    <measurement group_id="O2" value="84.4"/>
                    <measurement group_id="O3" value="82.6"/>
                    <measurement group_id="O4" value="80.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.4"/>
                    <measurement group_id="O2" value="15.6"/>
                    <measurement group_id="O3" value="17.4"/>
                    <measurement group_id="O4" value="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes of Functional Parameter Mid-Regional Pro-Adrenomedullin (MR-proADM) During Stay at ICU</title>
        <description>Changes of Mid-Regional pro-Adrenomedullin (MR-proADM) between baseline and last observed value. MR-proADM was measured in the blood samples taken during the ICU stay prior to start of IMP infusion (day 1) and within the time frame of 24 hours (+/- 10 hours) after end of IMP infusion (day 2), at 48 hours, 96 hours and 144 hours after end of infusion (+/- 10 hours) or between scheduled assessments, if discharged earlier from ICU (whatever comes first).</description>
        <time_frame>28 days</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 2 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 2 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 4 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 4 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Adrecizumab Overall</title>
            <description>Treatment Arm A and Treatment Arm B combined</description>
          </group>
          <group group_id="O4">
            <title>Control Group</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of Placebo of Adrecizumab&#xD;
Placebo: Single i.v. dose of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes of Functional Parameter Mid-Regional Pro-Adrenomedullin (MR-proADM) During Stay at ICU</title>
          <description>Changes of Mid-Regional pro-Adrenomedullin (MR-proADM) between baseline and last observed value. MR-proADM was measured in the blood samples taken during the ICU stay prior to start of IMP infusion (day 1) and within the time frame of 24 hours (+/- 10 hours) after end of IMP infusion (day 2), at 48 hours, 96 hours and 144 hours after end of infusion (+/- 10 hours) or between scheduled assessments, if discharged earlier from ICU (whatever comes first).</description>
          <population>Full Analysis Set</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="124"/>
                <count group_id="O4" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.029" spread="5.2829"/>
                    <measurement group_id="O2" value="-4.608" spread="4.9512"/>
                    <measurement group_id="O3" value="-4.815" spread="5.1006"/>
                    <measurement group_id="O4" value="-4.030" spread="5.2887"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes of Functional Parameter Inflammatory Marker Procalcitonine (PCT) During Stay at ICU</title>
        <description>Changes of inflammatory marker Procalcitonine (PCT) between baseline and last observed value. PCT was measured in the blood samples taken during the ICU stay prior to start of IMP infusion (day 1) and within the time frame of 24 hours (+/- 10 hours) after end of IMP infusion (day 2), at 48 hours, 96 hours and 144 hours after end of infusion (+/- 10 hours) or between scheduled assessments, if discharged earlier from ICU (whatever comes first).</description>
        <time_frame>28 days</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 2 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 2 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 4 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 4 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Adrecizumab Overall</title>
            <description>Treatment Arm A and Treatment Arm B combined</description>
          </group>
          <group group_id="O4">
            <title>Control Group</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of Placebo of Adrecizumab&#xD;
Placebo: Single i.v. dose of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes of Functional Parameter Inflammatory Marker Procalcitonine (PCT) During Stay at ICU</title>
          <description>Changes of inflammatory marker Procalcitonine (PCT) between baseline and last observed value. PCT was measured in the blood samples taken during the ICU stay prior to start of IMP infusion (day 1) and within the time frame of 24 hours (+/- 10 hours) after end of IMP infusion (day 2), at 48 hours, 96 hours and 144 hours after end of infusion (+/- 10 hours) or between scheduled assessments, if discharged earlier from ICU (whatever comes first).</description>
          <population>Full Analysis Set</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="128"/>
                <count group_id="O4" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.402" spread="125.0852"/>
                    <measurement group_id="O2" value="-52.661" spread="78.1064"/>
                    <measurement group_id="O3" value="-47.208" spread="103.2929"/>
                    <measurement group_id="O4" value="-37.219" spread="78.3425"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes of Functional Parameter Inflammatory Marker Interleukin-6 (IL-6) During Stay at ICU</title>
        <description>Changes of inflammatory marker Interleukin-6 (IL-6) between baseline and last observed value. IL-6 was measured in the blood samples taken during the ICU stay prior to start of IMP infusion (day 1) and within the time frame of 24 hours (+/- 10 hours) after end of IMP infusion (day 2), at 48 hours, 96 hours and 144 hours after end of infusion (+/- 10 hours) or between scheduled assessments, if discharged earlier from ICU (whatever comes first).</description>
        <time_frame>28 days</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 2 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 2 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 4 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 4 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Adrecizumab Overall</title>
            <description>Treatment Arm A and Treatment Arm B combined</description>
          </group>
          <group group_id="O4">
            <title>Control Group</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of Placebo of Adrecizumab&#xD;
Placebo: Single i.v. dose of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes of Functional Parameter Inflammatory Marker Interleukin-6 (IL-6) During Stay at ICU</title>
          <description>Changes of inflammatory marker Interleukin-6 (IL-6) between baseline and last observed value. IL-6 was measured in the blood samples taken during the ICU stay prior to start of IMP infusion (day 1) and within the time frame of 24 hours (+/- 10 hours) after end of IMP infusion (day 2), at 48 hours, 96 hours and 144 hours after end of infusion (+/- 10 hours) or between scheduled assessments, if discharged earlier from ICU (whatever comes first).</description>
          <population>Full Analysis Set</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="128"/>
                <count group_id="O4" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27648.3" spread="72859.19"/>
                    <measurement group_id="O2" value="-37780.4" spread="119945.41"/>
                    <measurement group_id="O3" value="-32872.7" spread="99694.28"/>
                    <measurement group_id="O4" value="-26236.2" spread="70315.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes of Functional Parameter Dipeptidyl Peptidase 3 (DPP3) During Stay at ICU</title>
        <description>Changes of dipeptidyl peptidase 3 (DPP3) between baseline and last observed value. DPP3 was measured in the blood samples taken during the ICU stay prior to start of IMP infusion (day 1) and within the time frame of 24 hours (+/- 10 hours) after end of IMP infusion (day 2), at 48 hours, 96 hours and 144 hours after end of infusion (+/- 10 hours) or between scheduled assessments, if discharged earlier from ICU (whatever comes first).</description>
        <time_frame>28 days</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 2 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 2 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 4 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 4 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Adrecizumab Overall</title>
            <description>Treatment Arm A and Treatment Arm B combined</description>
          </group>
          <group group_id="O4">
            <title>Control Group</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of Placebo of Adrecizumab&#xD;
Placebo: Single i.v. dose of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes of Functional Parameter Dipeptidyl Peptidase 3 (DPP3) During Stay at ICU</title>
          <description>Changes of dipeptidyl peptidase 3 (DPP3) between baseline and last observed value. DPP3 was measured in the blood samples taken during the ICU stay prior to start of IMP infusion (day 1) and within the time frame of 24 hours (+/- 10 hours) after end of IMP infusion (day 2), at 48 hours, 96 hours and 144 hours after end of infusion (+/- 10 hours) or between scheduled assessments, if discharged earlier from ICU (whatever comes first).</description>
          <population>Full Analysis Set</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="128"/>
                <count group_id="O4" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.56" spread="53.030"/>
                    <measurement group_id="O2" value="-12.47" spread="42.270"/>
                    <measurement group_id="O3" value="-12.03" spread="47.596"/>
                    <measurement group_id="O4" value="-9.38" spread="122.031"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vasopressor Use (Drug, Highest Dose)</title>
        <description>Vasopressor use (drug, highest dose). Vasopressor use was recorded from admission to ICU at time point of diagnosis of septic shock and daily thereafter from day 1 through day 28 or discharge from ICU (whatever comes first).</description>
        <time_frame>28 days</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 2 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 2 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 4 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 4 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Adrecizumab Overall</title>
            <description>Treatment Arm A and Treatment Arm B combined</description>
          </group>
          <group group_id="O4">
            <title>Control Group</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of Placebo of Adrecizumab&#xD;
Placebo: Single i.v. dose of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Vasopressor Use (Drug, Highest Dose)</title>
          <description>Vasopressor use (drug, highest dose). Vasopressor use was recorded from admission to ICU at time point of diagnosis of septic shock and daily thereafter from day 1 through day 28 or discharge from ICU (whatever comes first).</description>
          <population>Full Analysis Set</population>
          <units>μg/kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="149"/>
                <count group_id="O4" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>OTHER AGENTS FOR LOCAL ORAL TREATMENT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1236" spread="1.44760"/>
                    <measurement group_id="O2" value="2.1319" spread="1.53579"/>
                    <measurement group_id="O3" value="1.5018" spread="1.51582"/>
                    <measurement group_id="O4" value="1.9888" spread="2.60114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LOCAL HEMOSTATICS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1236" spread="1.44760"/>
                    <measurement group_id="O2" value="2.1319" spread="1.53579"/>
                    <measurement group_id="O3" value="1.5018" spread="1.51582"/>
                    <measurement group_id="O4" value="1.9888" spread="2.60114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADRENERGIC AND DOPAMINERGIC AGENTS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="149"/>
                    <count group_id="O4" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1414" spread="7.89069"/>
                    <measurement group_id="O2" value="1.7307" spread="2.03233"/>
                    <measurement group_id="O3" value="2.4124" spread="5.70006"/>
                    <measurement group_id="O4" value="1.8276" spread="4.86110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PHOSPHODIESTERASE INHIBITORS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                    <measurement group_id="O4" value="3.7763" spread="1.05962"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VASOPRESSIN AND ANALOGUES</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="144"/>
                    <count group_id="O4" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0324" spread="0.02597"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0.0289" spread="0.02265"/>
                    <measurement group_id="O4" value="0.0343" spread="0.02434"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SYMPATHOMIMETICS, PLAIN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1236" spread="1.44760"/>
                    <measurement group_id="O2" value="2.1319" spread="1.53579"/>
                    <measurement group_id="O3" value="1.5018" spread="1.51582"/>
                    <measurement group_id="O4" value="1.9888" spread="2.60114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>R03AA ALPHA- AND BETA-ADRENORECEPTOR AGONISTS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1236" spread="1.44760"/>
                    <measurement group_id="O2" value="2.1319" spread="1.53579"/>
                    <measurement group_id="O3" value="1.5018" spread="1.51582"/>
                    <measurement group_id="O4" value="1.9888" spread="2.60114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>R03CA ALPHA- AND BETA-ADRENORECEPTOR AGONISTS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1236" spread="1.44760"/>
                    <measurement group_id="O2" value="2.1319" spread="1.53579"/>
                    <measurement group_id="O3" value="1.5018" spread="1.51582"/>
                    <measurement group_id="O4" value="1.9888" spread="2.60114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SYMPATHOMIMETICS IN GLAUCOMA THERAPY</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1236" spread="1.44760"/>
                    <measurement group_id="O2" value="2.1319" spread="1.53579"/>
                    <measurement group_id="O3" value="1.5018" spread="1.51582"/>
                    <measurement group_id="O4" value="1.9888" spread="2.60114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HOMEOPATHIC PREPARATION</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1236" spread="1.44760"/>
                    <measurement group_id="O2" value="2.1319" spread="1.53579"/>
                    <measurement group_id="O3" value="1.5018" spread="1.51582"/>
                    <measurement group_id="O4" value="1.9888" spread="2.60114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Reported Outcomes : Quality of Life by Euro-QoL-5</title>
        <description>Patient reported outcomes: Quality of Life Form by EuroQoL Group, version &quot;Euro-QoL-5&quot; (day 28 and day 90). Change 1 = Visual analog scale (VAS) at discharge - VAS at day 90. Change 2 = VAS at day 28 - VAS at day 90. Minimum value on the scale is 0, maximum value on the scale is 100. A lower score indicates a worse outcome. As the change between two scores is calculated, a negative number indicates a worsening.</description>
        <time_frame>day 28 and day 90</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 2 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 2 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 4 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 4 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Adrecizumab Overall</title>
            <description>Treatment Arm A and Treatment Arm B combined</description>
          </group>
          <group group_id="O4">
            <title>Control Group</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of Placebo of Adrecizumab&#xD;
Placebo: Single i.v. dose of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Reported Outcomes : Quality of Life by Euro-QoL-5</title>
          <description>Patient reported outcomes: Quality of Life Form by EuroQoL Group, version &quot;Euro-QoL-5&quot; (day 28 and day 90). Change 1 = Visual analog scale (VAS) at discharge - VAS at day 90. Change 2 = VAS at day 28 - VAS at day 90. Minimum value on the scale is 0, maximum value on the scale is 100. A lower score indicates a worse outcome. As the change between two scores is calculated, a negative number indicates a worsening.</description>
          <population>Full Analysis Set</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="149"/>
                <count group_id="O4" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="30"/>
                    <count group_id="O3" value="57"/>
                    <count group_id="O4" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.4" spread="22.11"/>
                    <measurement group_id="O2" value="-19.3" spread="22.76"/>
                    <measurement group_id="O3" value="-16.5" spread="22.45"/>
                    <measurement group_id="O4" value="-7.6" spread="27.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="63"/>
                    <count group_id="O4" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.8" spread="16.21"/>
                    <measurement group_id="O2" value="-10.2" spread="19.40"/>
                    <measurement group_id="O3" value="-11.0" spread="17.83"/>
                    <measurement group_id="O4" value="-5.9" spread="21.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vital Signs</title>
        <description>Vital signs: heart rate (beat per minute) Change from baseline to Day 7.</description>
        <time_frame>7 days</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 2 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 2 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 4 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 4 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Adrecizumab Overall</title>
            <description>Treatment Arm A and Treatment Arm B combined</description>
          </group>
          <group group_id="O4">
            <title>Control Group</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of Placebo of Adrecizumab&#xD;
Placebo: Single i.v. dose of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Signs</title>
          <description>Vital signs: heart rate (beat per minute) Change from baseline to Day 7.</description>
          <population>Full Analysis Set</population>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="88"/>
                <count group_id="O4" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Heart Rate Change Day 7 (Maximum)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" spread="33.24"/>
                    <measurement group_id="O2" value="4.3" spread="21.85"/>
                    <measurement group_id="O3" value="4.9" spread="27.46"/>
                    <measurement group_id="O4" value="13.5" spread="28.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart Rate Change Day 7 (Minimum)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.2" spread="22.91"/>
                    <measurement group_id="O2" value="-18.5" spread="20.53"/>
                    <measurement group_id="O3" value="-22.4" spread="21.96"/>
                    <measurement group_id="O4" value="-18.1" spread="24.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Penalized Sepsis Support Index (pSSI) at 28 Day Follow-up</title>
        <description>Penalized Sepsis Support Index (pSSI) at 28 day follow-up, is a version of the SSI where mortality is given extra weight: Patients being alive duringthe 14 days' follow up will have an SSI ranging up to 14 (as defined above), while patients who died within that period will be assigned a score of &quot;14 plus the number of days not being alive&quot;. Thus the weighted SSI score may range between zero and 28. A higher score means a worse outcome.</description>
        <time_frame>day 28</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 2 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 2 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 4 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 4 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Adrecizumab Overall</title>
            <description>Treatment Arm A and Treatment Arm B combined</description>
          </group>
          <group group_id="O4">
            <title>Control Group</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of Placebo of Adrecizumab&#xD;
Placebo: Single i.v. dose of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Penalized Sepsis Support Index (pSSI) at 28 Day Follow-up</title>
          <description>Penalized Sepsis Support Index (pSSI) at 28 day follow-up, is a version of the SSI where mortality is given extra weight: Patients being alive duringthe 14 days' follow up will have an SSI ranging up to 14 (as defined above), while patients who died within that period will be assigned a score of &quot;14 plus the number of days not being alive&quot;. Thus the weighted SSI score may range between zero and 28. A higher score means a worse outcome.</description>
          <population>Full Analysis Set</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="145"/>
                <count group_id="O4" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8" spread="11.34"/>
                    <measurement group_id="O2" value="14.8" spread="10.87"/>
                    <measurement group_id="O3" value="14.3" spread="11.07"/>
                    <measurement group_id="O4" value="13.2" spread="11.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vasopressor Use (Drug, Lowest Dose)</title>
        <description>Vasopressor use (drug, lowest dose). Vasopressor use was recorded from admission to ICU at time point of diagnosis of septic shock and daily thereafter from day 1 through day 28 or discharge from ICU (whatever comes first).</description>
        <time_frame>28 days</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 2 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 2 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 4 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 4 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Adrecizumab Overall</title>
            <description>Treatment Arm A and Treatment Arm B combined</description>
          </group>
          <group group_id="O4">
            <title>Control Group</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of Placebo of Adrecizumab&#xD;
Placebo: Single i.v. dose of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Vasopressor Use (Drug, Lowest Dose)</title>
          <description>Vasopressor use (drug, lowest dose). Vasopressor use was recorded from admission to ICU at time point of diagnosis of septic shock and daily thereafter from day 1 through day 28 or discharge from ICU (whatever comes first).</description>
          <population>Full Analysis Set</population>
          <units>μg/kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="149"/>
                <count group_id="O4" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>OTHER AGENTS FOR LOCAL ORAL TREATMENT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0504" spread="1.49124"/>
                    <measurement group_id="O2" value="0.6053" spread="0.78343"/>
                    <measurement group_id="O3" value="0.8835" spread="1.26032"/>
                    <measurement group_id="O4" value="0.1611" spread="0.26523"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LOCAL HEMOSTATICS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0504" spread="1.49124"/>
                    <measurement group_id="O2" value="0.6053" spread="0.78343"/>
                    <measurement group_id="O3" value="0.8835" spread="1.26032"/>
                    <measurement group_id="O4" value="0.1611" spread="0.26523"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADRENERGIC AND DOPAMINERGIC AGENTS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="149"/>
                    <count group_id="O4" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0570" spread="0.15449"/>
                    <measurement group_id="O2" value="0.0358" spread="0.05762"/>
                    <measurement group_id="O3" value="0.0461" spread="0.11518"/>
                    <measurement group_id="O4" value="0.0528" spread="0.09866"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PHOSPHODIESTERASE INHIBITORS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                    <measurement group_id="O4" value="1.0824" spread="1.29168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VASOPRESSIN AND ANALOGUES</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0258" spread="0.02926"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0.0249" spread="0.02412"/>
                    <measurement group_id="O4" value="0.0259" spread="0.02520"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SYMPATHOMIMETICS, PLAIN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0504" spread="1.49124"/>
                    <measurement group_id="O2" value="0.6053" spread="0.78343"/>
                    <measurement group_id="O3" value="0.8835" spread="1.26032"/>
                    <measurement group_id="O4" value="0.1611" spread="0.26523"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>R03AA ALPHA- AND BETA-ADRENORECEPTOR AGONISTS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0504" spread="1.49124"/>
                    <measurement group_id="O2" value="0.6053" spread="0.78343"/>
                    <measurement group_id="O3" value="0.8835" spread="1.26032"/>
                    <measurement group_id="O4" value="0.1611" spread="0.26523"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>R03CA ALPHA- AND BETA-ADRENORECEPTOR AGONISTS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0504" spread="1.49124"/>
                    <measurement group_id="O2" value="0.6053" spread="0.78343"/>
                    <measurement group_id="O3" value="0.8835" spread="1.26032"/>
                    <measurement group_id="O4" value="0.1611" spread="0.26523"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SYMPATHOMIMETICS IN GLAUCOMA THERAPY</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0504" spread="1.49124"/>
                    <measurement group_id="O2" value="0.6053" spread="0.78343"/>
                    <measurement group_id="O3" value="0.8835" spread="1.26032"/>
                    <measurement group_id="O4" value="0.1611" spread="0.26523"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HOMEOPATHIC PREPARATION</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0504" spread="1.49124"/>
                    <measurement group_id="O2" value="0.6053" spread="0.78343"/>
                    <measurement group_id="O3" value="0.8835" spread="1.26032"/>
                    <measurement group_id="O4" value="0.1611" spread="0.26523"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vasopressor Use (Drug, Duration)</title>
        <description>Vasopressor use (drug, duration). Vasopressor use was recorded from admission to ICU at time point of diagnosis of septic shock and daily thereafter from day 1 through day 28 or discharge from ICU (whatever comes first).</description>
        <time_frame>28 days</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 2 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 2 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 4 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 4 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Adrecizumab Overall</title>
            <description>Treatment Arm A and Treatment Arm B combined</description>
          </group>
          <group group_id="O4">
            <title>Control Group</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of Placebo of Adrecizumab&#xD;
Placebo: Single i.v. dose of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Vasopressor Use (Drug, Duration)</title>
          <description>Vasopressor use (drug, duration). Vasopressor use was recorded from admission to ICU at time point of diagnosis of septic shock and daily thereafter from day 1 through day 28 or discharge from ICU (whatever comes first).</description>
          <population>Full Analysis Set</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="149"/>
                <count group_id="O4" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>OTHER AGENTS FOR LOCAL ORAL TREATMENT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.67" spread="1.658"/>
                    <measurement group_id="O2" value="1.50" spread="0.837"/>
                    <measurement group_id="O3" value="1.60" spread="1.352"/>
                    <measurement group_id="O4" value="1.78" spread="1.641"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LOCAL HEMOSTATICS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.67" spread="1.658"/>
                    <measurement group_id="O2" value="1.50" spread="0.837"/>
                    <measurement group_id="O3" value="1.60" spread="1.352"/>
                    <measurement group_id="O4" value="1.78" spread="1.641"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADRENERGIC AND DOPAMINERGIC AGENTS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="145"/>
                    <count group_id="O4" value="150"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" spread="1.767"/>
                    <measurement group_id="O2" value="3.18" spread="2.183"/>
                    <measurement group_id="O3" value="3.10" spread="1.994"/>
                    <measurement group_id="O4" value="3.34" spread="2.512"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PHOSPHODIESTERASE INHIBITORS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                    <measurement group_id="O4" value="4.00" spread="1.732"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VASOPRESSIN AND ANALOGUES</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.75" spread="0.500"/>
                    <measurement group_id="O2" value="3.00" spread="1.673"/>
                    <measurement group_id="O3" value="2.50" spread="1.434"/>
                    <measurement group_id="O4" value="2.21" spread="1.701"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SYMPATHOMIMETICS, PLAIN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.67" spread="1.658"/>
                    <measurement group_id="O2" value="1.50" spread="0.837"/>
                    <measurement group_id="O3" value="1.60" spread="1.352"/>
                    <measurement group_id="O4" value="1.70" spread="1.567"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SYMPATHOMIMETICS, COMBINATIONS EXCL. CORTICOSTEROIDS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SYMPATHOMIMETICS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>R03AA ALPHA- AND BETA-ADRENORECEPTOR AGONISTS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.67" spread="1.658"/>
                    <measurement group_id="O2" value="1.50" spread="0.837"/>
                    <measurement group_id="O3" value="1.60" spread="1.352"/>
                    <measurement group_id="O4" value="1.78" spread="1.641"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>R03CA ALPHA- AND BETA-ADRENORECEPTOR AGONISTS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.67" spread="1.658"/>
                    <measurement group_id="O2" value="1.50" spread="0.837"/>
                    <measurement group_id="O3" value="1.60" spread="1.352"/>
                    <measurement group_id="O4" value="1.78" spread="1.641"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SYMPATHOMIMETICS IN GLAUCOMA THERAPY</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.67" spread="1.658"/>
                    <measurement group_id="O2" value="1.50" spread="0.837"/>
                    <measurement group_id="O3" value="1.60" spread="1.352"/>
                    <measurement group_id="O4" value="1.78" spread="1.641"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SYMPATHOMIMETICS EXCL. ANTIGLAUCOMA PREPARATIONS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SYMPATHOMIMETICS USED AS DECONGESTANTS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HOMEOPATHIC PREPARATION</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.67" spread="1.658"/>
                    <measurement group_id="O2" value="1.50" spread="0.837"/>
                    <measurement group_id="O3" value="1.60" spread="1.352"/>
                    <measurement group_id="O4" value="1.78" spread="1.641"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Renal Function (penKid)</title>
        <description>Change in renal function as change in penKid (day 3 - day 1, day 7 - day 1). penKid was measured in the blood samples taken during the ICU stay prior to start of IMP infusion (day 1) and within the time frame of 24 hours (+/- 10 hours) after end of IMP infusion (day 2), at 48 hours, 96 hours and 144 hours after end of infusion (+/- 10 hours) or between scheduled assessments, if discharged earlier from ICU (whatever comes first).</description>
        <time_frame>day 1, day 3 and day 7</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 2 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 2 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 4 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 4 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Adrecizumab Overall</title>
            <description>Treatment Arm A and Treatment Arm B combined</description>
          </group>
          <group group_id="O4">
            <title>Control Group</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of Placebo of Adrecizumab&#xD;
Placebo: Single i.v. dose of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Renal Function (penKid)</title>
          <description>Change in renal function as change in penKid (day 3 - day 1, day 7 - day 1). penKid was measured in the blood samples taken during the ICU stay prior to start of IMP infusion (day 1) and within the time frame of 24 hours (+/- 10 hours) after end of IMP infusion (day 2), at 48 hours, 96 hours and 144 hours after end of infusion (+/- 10 hours) or between scheduled assessments, if discharged earlier from ICU (whatever comes first).</description>
          <population>Full Analysis Set</population>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="145"/>
                <count group_id="O4" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PenKid change baseline to day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="145"/>
                    <count group_id="O4" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.3" spread="57.25"/>
                    <measurement group_id="O2" value="-21.4" spread="59.07"/>
                    <measurement group_id="O3" value="-24.8" spread="58.10"/>
                    <measurement group_id="O4" value="-34.8" spread="63.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PenKid change baseline to day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="74"/>
                    <count group_id="O3" value="143"/>
                    <count group_id="O4" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.5" spread="83.88"/>
                    <measurement group_id="O2" value="-19.7" spread="70.80"/>
                    <measurement group_id="O3" value="-19.6" spread="77.11"/>
                    <measurement group_id="O4" value="-29.8" spread="83.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vital Signs - Blood Pressure</title>
        <description>Vital signs: blood pressure - mean arterial pressure (MAP) mmHg Change from baseline to Day 7.</description>
        <time_frame>7 days</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 2 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 2 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 4 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 4 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Adrecizumab Overall</title>
            <description>Treatment Arm A and Treatment Arm B combined</description>
          </group>
          <group group_id="O4">
            <title>Control Group</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of Placebo of Adrecizumab&#xD;
Placebo: Single i.v. dose of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Signs - Blood Pressure</title>
          <description>Vital signs: blood pressure - mean arterial pressure (MAP) mmHg Change from baseline to Day 7.</description>
          <population>Full Analysis Set</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="88"/>
                <count group_id="O4" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MAP Change Day 7 (Maximum)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.5" spread="22.26"/>
                    <measurement group_id="O2" value="28.2" spread="16.29"/>
                    <measurement group_id="O3" value="28.8" spread="19.13"/>
                    <measurement group_id="O4" value="31.7" spread="21.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MAP Change Day 7 (Minimum)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.6" spread="17.20"/>
                    <measurement group_id="O2" value="-6.5" spread="11.51"/>
                    <measurement group_id="O3" value="-7.9" spread="14.37"/>
                    <measurement group_id="O4" value="-8.7" spread="18.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>In Sub-study Key Pharmacokinetic Parameters Peak Plasma Concentrations (Cmax) Are to be Determined in 80 Patients</title>
        <description>peak plasma concentrations (Cmax). Time points at which blood samples were taken prior IMP administration, at 30 min, 24 hrs, 48 hrs , 96 hrs, 144 hrs, 648 hrs after IMP administration.</description>
        <time_frame>28 days</time_frame>
        <population>Pharmacokinetic Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 2 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 2 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 4 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 4 mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>In Sub-study Key Pharmacokinetic Parameters Peak Plasma Concentrations (Cmax) Are to be Determined in 80 Patients</title>
          <description>peak plasma concentrations (Cmax). Time points at which blood samples were taken prior IMP administration, at 30 min, 24 hrs, 48 hrs , 96 hrs, 144 hrs, 648 hrs after IMP administration.</description>
          <population>Pharmacokinetic Analysis Set</population>
          <units>μg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.193" spread="10.3942"/>
                    <measurement group_id="O2" value="86.854" spread="22.2438"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>In Sub-study Key Pharmacokinetic Parameters Time to Cmax (Tmax) Are to be Determined in 80 Patients</title>
        <description>Time to Cmax (tmax) in hours (h)</description>
        <time_frame>28 days</time_frame>
        <population>Pharmacokinetic Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 2 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 2 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 4 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 4 mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>In Sub-study Key Pharmacokinetic Parameters Time to Cmax (Tmax) Are to be Determined in 80 Patients</title>
          <description>Time to Cmax (tmax) in hours (h)</description>
          <population>Pharmacokinetic Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0.25 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.37 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.42 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.45 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.47 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.5 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.57 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.58 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.67 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.73 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2.5 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>21.97 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24.75 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25.12 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>In Sub-study Key Pharmacokinetic Parameter AUC is to be Determined in 80 Patients</title>
        <description>systemic exposure : Area under the plasma concentration versus time curve (AUC). Time points at which blood samples were taken prior IMP administration, at 30 min, 24 hrs, 48 hrs , 96 hrs, 144 hrs, 648 hrs after IMP administration.</description>
        <time_frame>28 days</time_frame>
        <population>Pharmacokinetic Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 2 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 2 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 4 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 4 mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>In Sub-study Key Pharmacokinetic Parameter AUC is to be Determined in 80 Patients</title>
          <description>systemic exposure : Area under the plasma concentration versus time curve (AUC). Time points at which blood samples were taken prior IMP administration, at 30 min, 24 hrs, 48 hrs , 96 hrs, 144 hrs, 648 hrs after IMP administration.</description>
          <population>Pharmacokinetic Analysis Set</population>
          <units>h*μg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4910.33" spread="1222.414"/>
                    <measurement group_id="O2" value="11245.28" spread="3462.585"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>In Sub-study Key Pharmacokinetic Parameter Volume of Distribution is to be Determined in 80 Patients</title>
        <description>volume of distribution (V). Time points at which blood samples were taken prior IMP administration, at 30 min, 24 hrs, 48 hrs , 96 hrs, 144 hrs, 648 hrs after IMP administration.</description>
        <time_frame>28 days</time_frame>
        <population>Pharmacokinetic Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 2 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 2 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 4 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 4 mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>In Sub-study Key Pharmacokinetic Parameter Volume of Distribution is to be Determined in 80 Patients</title>
          <description>volume of distribution (V). Time points at which blood samples were taken prior IMP administration, at 30 min, 24 hrs, 48 hrs , 96 hrs, 144 hrs, 648 hrs after IMP administration.</description>
          <population>Pharmacokinetic Analysis Set</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.277" spread="1.9220"/>
                    <measurement group_id="O2" value="3.737" spread="0.9427"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>In Sub-study Key Pharmacokinetic Parameter Systemic Clearance is to be Determined in 80 Patients</title>
        <description>systemic clearance (CL). Time points at which blood samples were taken prior IMP administration, at 30 min, 24 hrs, 48 hrs , 96 hrs, 144 hrs, 648 hrs after IMP administration.</description>
        <time_frame>28 days</time_frame>
        <population>Pharmacokinetic Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 2 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 2 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 4 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 4 mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>In Sub-study Key Pharmacokinetic Parameter Systemic Clearance is to be Determined in 80 Patients</title>
          <description>systemic clearance (CL). Time points at which blood samples were taken prior IMP administration, at 30 min, 24 hrs, 48 hrs , 96 hrs, 144 hrs, 648 hrs after IMP administration.</description>
          <population>Pharmacokinetic Analysis Set</population>
          <units>L/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0286" spread="0.00790"/>
                    <measurement group_id="O2" value="0.0280" spread="0.00826"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>In Sub-study Key Pharmacokinetic Parameter Elimination Half-life is to be Determined in 80 Patients</title>
        <description>elimination half-life (t½). Time points at which blood samples were taken prior IMP administration, at 30 min, 24 hrs, 48 hrs , 96 hrs, 144 hrs, 648 hrs after IMP administration.</description>
        <time_frame>28 days</time_frame>
        <population>Pharmacokinetic Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 2 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 2 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 4 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 4 mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>In Sub-study Key Pharmacokinetic Parameter Elimination Half-life is to be Determined in 80 Patients</title>
          <description>elimination half-life (t½). Time points at which blood samples were taken prior IMP administration, at 30 min, 24 hrs, 48 hrs , 96 hrs, 144 hrs, 648 hrs after IMP administration.</description>
          <population>Pharmacokinetic Analysis Set</population>
          <units>h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206.48" spread="43.809"/>
                    <measurement group_id="O2" value="177.90" spread="44.250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Endpoints for Primary Objective (Safety and Tolerability of Adrecizumab: Severity and Frequency of TEAEs) - Mild Severity</title>
        <description>The endpoints for the primary objective are to determine over the 90 days study period. Number of participants with treatment-emergent adverse events per treatment group with mild severity treatment emergent events.</description>
        <time_frame>90 days</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 2 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 2 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 4 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 4 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Adrecizumab Overall</title>
            <description>Treatment Arm A and Treatment Arm B combined</description>
          </group>
          <group group_id="O4">
            <title>Control Group</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of Placebo of Adrecizumab&#xD;
Placebo: Single i.v. dose of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Endpoints for Primary Objective (Safety and Tolerability of Adrecizumab: Severity and Frequency of TEAEs) - Mild Severity</title>
          <description>The endpoints for the primary objective are to determine over the 90 days study period. Number of participants with treatment-emergent adverse events per treatment group with mild severity treatment emergent events.</description>
          <population>Safety Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="149"/>
                <count group_id="O4" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="85"/>
                    <measurement group_id="O4" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Endpoints for Primary Objective (Safety and Tolerability of Adrecizumab: Severity and Frequency of TEAEs) - Moderate Severity</title>
        <description>The endpoints for the primary objective are to determine over the 90 days study period. Number of participants with treatment-emergent adverse events per treatment group with moderate severity treatment emergent events.</description>
        <time_frame>90 days</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 2 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 2 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 4 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 4 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Adrecizumab Overall</title>
            <description>Treatment Arm A and Treatment Arm B combined</description>
          </group>
          <group group_id="O4">
            <title>Control Group</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of Placebo of Adrecizumab&#xD;
Placebo: Single i.v. dose of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Endpoints for Primary Objective (Safety and Tolerability of Adrecizumab: Severity and Frequency of TEAEs) - Moderate Severity</title>
          <description>The endpoints for the primary objective are to determine over the 90 days study period. Number of participants with treatment-emergent adverse events per treatment group with moderate severity treatment emergent events.</description>
          <population>Safety Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="149"/>
                <count group_id="O4" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="60"/>
                    <measurement group_id="O3" value="114"/>
                    <measurement group_id="O4" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Endpoints for Primary Objective (Safety and Tolerability of Adrecizumab: Severity and Frequency of TEAEs) - Severe Severity</title>
        <description>The endpoints for the primary objective are to determine over the 90 days study period. Number of participants with treatment-emergent adverse events per treatment group with severe severity treatment emergent events.</description>
        <time_frame>90 days</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 2 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 2 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 4 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 4 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Adrecizumab Overall</title>
            <description>Treatment Arm A and Treatment Arm B combined</description>
          </group>
          <group group_id="O4">
            <title>Control Group</title>
            <description>Intravenous infusion over approximately 1 hour of single i.v. dose of Placebo of Adrecizumab&#xD;
Placebo: Single i.v. dose of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Endpoints for Primary Objective (Safety and Tolerability of Adrecizumab: Severity and Frequency of TEAEs) - Severe Severity</title>
          <description>The endpoints for the primary objective are to determine over the 90 days study period. Number of participants with treatment-emergent adverse events per treatment group with severe severity treatment emergent events.</description>
          <population>Safety Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="149"/>
                <count group_id="O4" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="54"/>
                    <measurement group_id="O3" value="105"/>
                    <measurement group_id="O4" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All Adverse Events whether serious or non-serious and judged related or unrelated to the study drug occurring during the study period (Day 1 (inclusion and single IMP administration) until 90 days after study drug administration (=Day1)) were collected. The study period was 2 years.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment Arm A</title>
          <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 2 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 2 mg/kg</description>
        </group>
        <group group_id="E2">
          <title>Treatment Arm B</title>
          <description>Intravenous infusion over approximately 1 hour of single i.v. dose of 4 mg/kg Adrecizumab&#xD;
Adrecizumab: Single i.v. dose of 4 mg/kg</description>
        </group>
        <group group_id="E3">
          <title>Control Group</title>
          <description>Intravenous infusion over approximately 1 hour of single i.v. dose of Placebo of Adrecizumab&#xD;
Placebo: Single i.v. dose of placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (22.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="96" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Splenic necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Conduction disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Heart valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Stress cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Ventricular hypokinesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Primary adrenal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Intra-abdominal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Fistula of small intestine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Gastrointestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Duodenal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Small intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Mechanical ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Intra-abdominal fluid collection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Oesophageal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Gastroduodenal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Abdominal wall haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Peritoneal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Catheter site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Multimorbidity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Critical illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Hepatic necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Septic shock</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="72"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Infectious pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Necrotising fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Clostridium colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Enterococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Urinary tract infection enterococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Acinetobacter bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Herpes simplex pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Herpes sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Escherichia peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Psoas abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Intervertebral discitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Subdiaphragmatic abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Myocarditis septic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Wound abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Pelvic abscess</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Klebsiella bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Pulmonary sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Abdominal wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Weaning failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Intestinal anastomosis complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Endotracheal intubation complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Eschar</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Gastrointestinal stoma complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Electrocardiogram repolarisation abnormality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Blood lactic acid increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperlactacidaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cholangiocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Oesophageal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Intensive care unit acquired weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Status epilepticus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Osmotic demyelination syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Embedded device</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Renal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Bronchial haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Respiratory fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Bronchial obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Pharyngeal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Respiratory acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Oedema blister</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Skin necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Withdrawal of life support</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriovenous fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Arterial haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Peripheral artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Jugular vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (22.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="84" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="77"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Hypernatraemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="72"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="77"/>
                <counts group_id="E3" events="18" subjects_affected="17" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jens Zimmermann</name_or_title>
      <organization>Adrenomed AG</organization>
      <phone>+49 (0) 3302 20 77 810</phone>
      <email>jzimmermann@adrenomed.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

